EA024109B1 - Ингибиторы протеинкиназ - Google Patents

Info

Publication number

EA024109B1

EA024109B1 EA201001619A EA201001619A EA024109B1 EA 024109 B1 EA024109 B1 EA 024109B1 EA 201001619 A EA201001619 A EA 201001619A EA 201001619 A EA201001619 A EA 201001619A EA 024109 B1 EA024109 B1 EA 024109B1

Authority

EA

Eurasian Patent Office

Prior art keywords

compound

compounds

group

alkyl

cells

Prior art date

2008-04-16

Links

• Espacenet
• Global Dossier
• Discuss

• 239000003112 inhibitor Substances 0.000 title abstract description 46
• 102000001253 Protein Kinase Human genes 0.000 title description 12
• 108060006633 protein kinase Proteins 0.000 title description 12
• 150000001875 compounds Chemical class 0.000 claims abstract description 554
• 238000000034 method Methods 0.000 claims abstract description 321
• 230000000694 effects Effects 0.000 claims abstract description 72
• 230000001404 mediated effect Effects 0.000 claims abstract description 64
• 150000003839 salts Chemical class 0.000 claims abstract description 55
• 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 21
• -1 amino, hydroxy, aminocarbonyl Chemical group 0.000 claims description 256
• 239000000203 mixture Substances 0.000 claims description 127
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 103
• 108091000080 Phosphotransferase Proteins 0.000 claims description 62
• 102000020233 phosphotransferase Human genes 0.000 claims description 62
• 125000003118 aryl group Chemical group 0.000 claims description 59
• 125000000623 heterocyclic group Chemical group 0.000 claims description 51
• 125000001424 substituent group Chemical group 0.000 claims description 48
• 229910052739 hydrogen Inorganic materials 0.000 claims description 37
• 230000019491 signal transduction Effects 0.000 claims description 34
• 229910052799 carbon Inorganic materials 0.000 claims description 33
• 238000011282 treatment Methods 0.000 claims description 29
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 28
• 125000004432 carbon atom Chemical group C* 0.000 claims description 23
• 230000002401 inhibitory effect Effects 0.000 claims description 18
• 229910052757 nitrogen Inorganic materials 0.000 claims description 18
• 125000005842 heteroatom Chemical group 0.000 claims description 15
• 201000011510 cancer Diseases 0.000 claims description 13
• 239000003937 drug carrier Substances 0.000 claims description 13
• 206010028980 Neoplasm Diseases 0.000 claims description 12
• 125000003545 alkoxy group Chemical group 0.000 claims description 10
• 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 10
• 229910052717 sulfur Chemical group 0.000 claims description 10
• 239000003085 diluting agent Substances 0.000 claims description 9
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 9
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 8
• 230000008054 signal transmission Effects 0.000 claims description 8
• 239000011593 sulfur Chemical group 0.000 claims description 8
• 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 7
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 7
• 229920006395 saturated elastomer Polymers 0.000 claims description 7
• RMNLLPXCNDZJMJ-IDVLALEDSA-N 2-[[(1r,2s)-2-aminocyclohexyl]amino]-4-[3-(triazol-2-yl)anilino]pyrimidine-5-carboxamide;hydrochloride Chemical compound Cl.N[C@H]1CCCC[C@H]1NC1=NC=C(C(N)=O)C(NC=2C=C(C=CC=2)N2N=CC=N2)=N1 RMNLLPXCNDZJMJ-IDVLALEDSA-N 0.000 claims description 6
• 125000004122 cyclic group Chemical group 0.000 claims description 6
• 125000004043 oxo group Chemical group O=* 0.000 claims description 6
• 229910052760 oxygen Inorganic materials 0.000 claims description 5
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 4
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 4
• 239000001301 oxygen Substances 0.000 claims description 4
• 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 3
• 125000006517 heterocyclyl carbonyl group Chemical group 0.000 claims description 3
• 125000000446 sulfanediyl group Chemical group *S* 0.000 claims description 3
• 125000006636 (C3-C8) cycloalkylcarbonyl group Chemical group 0.000 claims description 2
• 101150118034 ARC5 gene Proteins 0.000 claims 1
• 241000549194 Euonymus europaeus Species 0.000 claims 1
• 101000958791 Homo sapiens Mitotic-spindle organizing protein 1 Proteins 0.000 claims 1
• 101001137510 Homo sapiens Outer dynein arm-docking complex subunit 2 Proteins 0.000 claims 1
• 101001059443 Homo sapiens Serine/threonine-protein kinase MARK1 Proteins 0.000 claims 1
• 102100038336 Mitotic-spindle organizing protein 1 Human genes 0.000 claims 1
• 102100035706 Outer dynein arm-docking complex subunit 2 Human genes 0.000 claims 1
• 101100323633 Phaseolus vulgaris ARC5B gene Proteins 0.000 claims 1
• 101100487677 Salmonella typhimurium (strain LT2 / SGSC1412 / ATCC 700720) yadU gene Proteins 0.000 claims 1
• 102100028921 Serine/threonine-protein kinase MARK1 Human genes 0.000 claims 1
• 238000004806 packaging method and process Methods 0.000 claims 1
• 239000002023 wood Substances 0.000 claims 1
• 230000005764 inhibitory process Effects 0.000 abstract description 29
• 239000000543 intermediate Substances 0.000 abstract description 20
• 208000015914 Non-Hodgkin lymphomas Diseases 0.000 abstract description 18
• 208000007536 Thrombosis Diseases 0.000 abstract description 14
• 238000002360 preparation method Methods 0.000 abstract description 12
• 208000010110 spontaneous platelet aggregation Diseases 0.000 abstract description 5
• 230000002411 adverse Effects 0.000 abstract 1
• 201000006417 multiple sclerosis Diseases 0.000 description 268
• KZZKOVLJUKWSKX-UHFFFAOYSA-N cyclobutanamine Chemical compound NC1CCC1 KZZKOVLJUKWSKX-UHFFFAOYSA-N 0.000 description 144
• 210000004027 cell Anatomy 0.000 description 109
• PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 107
• HTJDQJBWANPRPF-UHFFFAOYSA-N Cyclopropylamine Chemical compound NC1CC1 HTJDQJBWANPRPF-UHFFFAOYSA-N 0.000 description 107
• 125000006317 cyclopropyl amino group Chemical group 0.000 description 85
• 125000000217 alkyl group Chemical group 0.000 description 84
• 150000002431 hydrogen Chemical class 0.000 description 62
• 201000010099 disease Diseases 0.000 description 55
• 239000000243 solution Substances 0.000 description 53
• 235000014510 cooky Nutrition 0.000 description 48
• 208000035475 disorder Diseases 0.000 description 47
• 125000001072 heteroaryl group Chemical group 0.000 description 45
• 102000005962 receptors Human genes 0.000 description 44
• 108020003175 receptors Proteins 0.000 description 44
• 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 41
• 125000000753 cycloalkyl group Chemical group 0.000 description 40
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 39
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 38
• QDXGKRWDQCEABB-UHFFFAOYSA-N pyrimidine-5-carboxamide Chemical class NC(=O)C1=CN=CN=C1 QDXGKRWDQCEABB-UHFFFAOYSA-N 0.000 description 36
• WFQDTOYDVUWQMS-UHFFFAOYSA-N 1-fluoro-4-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C=C1 WFQDTOYDVUWQMS-UHFFFAOYSA-N 0.000 description 34
• 125000006311 cyclobutyl amino group Chemical group [H]N(*)C1([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 33
• 208000023275 Autoimmune disease Diseases 0.000 description 32
• 239000001257 hydrogen Substances 0.000 description 29
• 108090000623 proteins and genes Proteins 0.000 description 29
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 28
• 102100024457 Cyclin-dependent kinase 9 Human genes 0.000 description 27
• 238000005481 NMR spectroscopy Methods 0.000 description 27
• 230000004913 activation Effects 0.000 description 26
• ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 25
• 239000003814 drug Substances 0.000 description 25
• 239000007787 solid Substances 0.000 description 25
• 230000015572 biosynthetic process Effects 0.000 description 24
• 230000014509 gene expression Effects 0.000 description 24
• 210000003719 b-lymphocyte Anatomy 0.000 description 23
• 238000006243 chemical reaction Methods 0.000 description 23
• 235000018102 proteins Nutrition 0.000 description 23
• 102000004169 proteins and genes Human genes 0.000 description 23
• 125000000304 alkynyl group Chemical group 0.000 description 22
• 125000000392 cycloalkenyl group Chemical group 0.000 description 22
• 208000032839 leukemia Diseases 0.000 description 22
• 238000003786 synthesis reaction Methods 0.000 description 22
• KIPSRYDSZQRPEA-UHFFFAOYSA-N 2,2,2-trifluoroethanamine Chemical compound NCC(F)(F)F KIPSRYDSZQRPEA-UHFFFAOYSA-N 0.000 description 21
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Natural products CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 20
• 206010020751 Hypersensitivity Diseases 0.000 description 20
• WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 20
• 125000003342 alkenyl group Chemical group 0.000 description 20
• 239000000546 pharmaceutical excipient Substances 0.000 description 19
• 239000000651 prodrug Substances 0.000 description 19
• 229940002612 prodrug Drugs 0.000 description 19
• 239000000725 suspension Substances 0.000 description 19
• 208000031261 Acute myeloid leukaemia Diseases 0.000 description 18
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
• 230000011664 signaling Effects 0.000 description 18
• 239000007858 starting material Substances 0.000 description 18
• 210000001519 tissue Anatomy 0.000 description 18
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 17
• 241000282414 Homo sapiens Species 0.000 description 17
• 239000000427 antigen Substances 0.000 description 17
• 108091007433 antigens Proteins 0.000 description 17
• 102000036639 antigens Human genes 0.000 description 17
• 238000004128 high performance liquid chromatography Methods 0.000 description 17
• 208000024891 symptom Diseases 0.000 description 17
• RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 16
• 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 16
• DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 16
• 230000004083 survival effect Effects 0.000 description 16
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 15
• 238000003556 assay Methods 0.000 description 15
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 15
• 239000003795 chemical substances by application Substances 0.000 description 15
• 239000002253 acid Substances 0.000 description 14
• 125000004429 atom Chemical group 0.000 description 14
• 229940079593 drug Drugs 0.000 description 14
• 230000037361 pathway Effects 0.000 description 14
• 239000002904 solvent Substances 0.000 description 14
• 230000000638 stimulation Effects 0.000 description 14
• 125000003107 substituted aryl group Chemical group 0.000 description 14
• 241000124008 Mammalia Species 0.000 description 13
• 239000002585 base Substances 0.000 description 13
• 238000009739 binding Methods 0.000 description 13
• 150000001721 carbon Chemical group 0.000 description 13
• 239000002552 dosage form Substances 0.000 description 13
• 150000002148 esters Chemical class 0.000 description 13
• IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 13
• 229910000041 hydrogen chloride Inorganic materials 0.000 description 13
• 238000006366 phosphorylation reaction Methods 0.000 description 13
• 150000003254 radicals Chemical class 0.000 description 13
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 12
• 206010025323 Lymphomas Diseases 0.000 description 12
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
• 230000027455 binding Effects 0.000 description 12
• 210000004204 blood vessel Anatomy 0.000 description 12
• 230000001419 dependent effect Effects 0.000 description 12
• 230000006870 function Effects 0.000 description 12
• 239000012074 organic phase Substances 0.000 description 12
• 230000026731 phosphorylation Effects 0.000 description 12
• 230000035755 proliferation Effects 0.000 description 12
• 208000037803 restenosis Diseases 0.000 description 12
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 11
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 11
• 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 11
• 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 11
• 230000001154 acute effect Effects 0.000 description 11
• 150000001412 amines Chemical class 0.000 description 11
• 239000005557 antagonist Substances 0.000 description 11
• 230000001413 cellular effect Effects 0.000 description 11
• 230000001684 chronic effect Effects 0.000 description 11
• 125000000524 functional group Chemical group 0.000 description 11
• 125000004435 hydrogen atom Chemical group [H]* 0.000 description 11
• 210000000056 organ Anatomy 0.000 description 11
• 206010039073 rheumatoid arthritis Diseases 0.000 description 11
• QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 10
• 208000002250 Hematologic Neoplasms Diseases 0.000 description 10
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 10
• 210000001744 T-lymphocyte Anatomy 0.000 description 10
• 208000006673 asthma Diseases 0.000 description 10
• 210000003958 hematopoietic stem cell Anatomy 0.000 description 10
• 239000000843 powder Substances 0.000 description 10
• 239000000047 product Substances 0.000 description 10
• 230000004044 response Effects 0.000 description 10
• 239000011734 sodium Substances 0.000 description 10
• 125000000547 substituted alkyl group Chemical group 0.000 description 10
• 229940124597 therapeutic agent Drugs 0.000 description 10
• 238000002054 transplantation Methods 0.000 description 10
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 10
• XTTIQGSLJBWVIV-UHFFFAOYSA-N 2-methyl-4-nitroaniline Chemical compound CC1=CC([N+]([O-])=O)=CC=C1N XTTIQGSLJBWVIV-UHFFFAOYSA-N 0.000 description 9
• 241000699670 Mus sp. Species 0.000 description 9
• KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 9
• 238000004458 analytical method Methods 0.000 description 9
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 9
• 238000002347 injection Methods 0.000 description 9
• 239000007924 injection Substances 0.000 description 9
• 230000003834 intracellular effect Effects 0.000 description 9
• 210000004072 lung Anatomy 0.000 description 9
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 9
• 229910052700 potassium Inorganic materials 0.000 description 9
• 230000008569 process Effects 0.000 description 9
• 239000011541 reaction mixture Substances 0.000 description 9
• 210000000130 stem cell Anatomy 0.000 description 9
• 238000003756 stirring Methods 0.000 description 9
• 102000004127 Cytokines Human genes 0.000 description 8
• 108090000695 Cytokines Proteins 0.000 description 8
• 241000282412 Homo Species 0.000 description 8
• 241001465754 Metazoa Species 0.000 description 8
• BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 8
• 230000002159 abnormal effect Effects 0.000 description 8
• 239000000556 agonist Substances 0.000 description 8
• 230000007815 allergy Effects 0.000 description 8
• 230000001363 autoimmune Effects 0.000 description 8
• 210000004369 blood Anatomy 0.000 description 8
• 239000008280 blood Substances 0.000 description 8
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 8
• RUJPPJYDHHAEEK-UHFFFAOYSA-N ethyl piperidine-4-carboxylate Chemical compound CCOC(=O)C1CCNCC1 RUJPPJYDHHAEEK-UHFFFAOYSA-N 0.000 description 8
• 210000000265 leukocyte Anatomy 0.000 description 8
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
• 125000004433 nitrogen atom Chemical group N* 0.000 description 8
• 230000002062 proliferating effect Effects 0.000 description 8
• 125000006239 protecting group Chemical group 0.000 description 8
• 239000000126 substance Substances 0.000 description 8
• 238000006467 substitution reaction Methods 0.000 description 8
• 230000001225 therapeutic effect Effects 0.000 description 8
• 208000027930 type IV hypersensitivity disease Diseases 0.000 description 8
• 230000003827 upregulation Effects 0.000 description 8
• 230000002792 vascular Effects 0.000 description 8
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 7
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 7
• 208000017604 Hodgkin disease Diseases 0.000 description 7
• 206010061218 Inflammation Diseases 0.000 description 7
• 201000003793 Myelodysplastic syndrome Diseases 0.000 description 7
• 206010052779 Transplant rejections Diseases 0.000 description 7
• 125000002947 alkylene group Chemical group 0.000 description 7
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 7
• 230000006378 damage Effects 0.000 description 7
• 238000011161 development Methods 0.000 description 7
• 230000018109 developmental process Effects 0.000 description 7
• 125000005843 halogen group Chemical group 0.000 description 7
• 210000003630 histaminocyte Anatomy 0.000 description 7
• 230000004054 inflammatory process Effects 0.000 description 7
• 238000001990 intravenous administration Methods 0.000 description 7
• 210000004698 lymphocyte Anatomy 0.000 description 7
• 210000002540 macrophage Anatomy 0.000 description 7
• 238000004519 manufacturing process Methods 0.000 description 7
• 208000010125 myocardial infarction Diseases 0.000 description 7
• 229920001223 polyethylene glycol Polymers 0.000 description 7
• 208000007056 sickle cell anemia Diseases 0.000 description 7
• 125000005017 substituted alkenyl group Chemical group 0.000 description 7
• 125000004426 substituted alkynyl group Chemical group 0.000 description 7
• 208000011580 syndromic disease Diseases 0.000 description 7
• AFVUJJNEILZYJQ-UHFFFAOYSA-N 1-[4-(4-aminophenyl)-1-piperazinyl]ethanone Chemical compound C1CN(C(=O)C)CCN1C1=CC=C(N)C=C1 AFVUJJNEILZYJQ-UHFFFAOYSA-N 0.000 description 6
• JJYPMNFTHPTTDI-UHFFFAOYSA-N 3-methylaniline Chemical compound CC1=CC=CC(N)=C1 JJYPMNFTHPTTDI-UHFFFAOYSA-N 0.000 description 6
• SKDHHIUENRGTHK-UHFFFAOYSA-N 4-nitrobenzoyl chloride Chemical compound [O-][N+](=O)C1=CC=C(C(Cl)=O)C=C1 SKDHHIUENRGTHK-UHFFFAOYSA-N 0.000 description 6
• 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 6
• 208000003950 B-cell lymphoma Diseases 0.000 description 6
• WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
• 102000008186 Collagen Human genes 0.000 description 6
• 108010035532 Collagen Proteins 0.000 description 6
• 208000010747 Hodgkins lymphoma Diseases 0.000 description 6
• CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 6
• KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
• WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 6
• 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 6
• YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 6
• JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 6
• 239000002202 Polyethylene glycol Substances 0.000 description 6
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
• 201000004681 Psoriasis Diseases 0.000 description 6
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
• 208000006011 Stroke Diseases 0.000 description 6
• 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 6
• 239000012190 activator Substances 0.000 description 6
• 125000004453 alkoxycarbonyl group Chemical group 0.000 description 6
• 150000001413 amino acids Chemical class 0.000 description 6
• 230000006907 apoptotic process Effects 0.000 description 6
• 239000012267 brine Substances 0.000 description 6
• 150000001732 carboxylic acid derivatives Chemical class 0.000 description 6
• 239000000969 carrier Substances 0.000 description 6
• 229920001436 collagen Polymers 0.000 description 6
• 210000004351 coronary vessel Anatomy 0.000 description 6
• 238000000684 flow cytometry Methods 0.000 description 6
• 238000005755 formation reaction Methods 0.000 description 6
• 238000009472 formulation Methods 0.000 description 6
• 239000012634 fragment Substances 0.000 description 6
• 229910052736 halogen Inorganic materials 0.000 description 6
• 210000002216 heart Anatomy 0.000 description 6
• 230000001965 increasing effect Effects 0.000 description 6
• 208000027866 inflammatory disease Diseases 0.000 description 6
• 238000007917 intracranial administration Methods 0.000 description 6
• 210000003734 kidney Anatomy 0.000 description 6
• 239000007788 liquid Substances 0.000 description 6
• 210000004185 liver Anatomy 0.000 description 6
• 125000000449 nitro group Chemical class [O-][N+](*)=O 0.000 description 6
• 230000002018 overexpression Effects 0.000 description 6
• HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 6
• 230000003393 splenic effect Effects 0.000 description 6
• 239000003826 tablet Substances 0.000 description 6
• FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 6
• 230000001732 thrombotic effect Effects 0.000 description 6
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 5
• 206010003210 Arteriosclerosis Diseases 0.000 description 5
• 108091008875 B cell receptors Proteins 0.000 description 5
• 208000012526 B-cell neoplasm Diseases 0.000 description 5
• 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 5
• KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical class NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 5
• 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 5
• 241000792859 Enema Species 0.000 description 5
• 102000004190 Enzymes Human genes 0.000 description 5
• 108090000790 Enzymes Proteins 0.000 description 5
• 108010054147 Hemoglobins Proteins 0.000 description 5
• 102000001554 Hemoglobins Human genes 0.000 description 5
• 206010062506 Heparin-induced thrombocytopenia Diseases 0.000 description 5
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
• 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 5
• 102100036314 Mitochondrial cardiolipin hydrolase Human genes 0.000 description 5
• 229910019142 PO4 Inorganic materials 0.000 description 5
• 206010042971 T-cell lymphoma Diseases 0.000 description 5
• 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 5
• 125000002252 acyl group Chemical group 0.000 description 5
• 229940024606 amino acid Drugs 0.000 description 5
• 229910021529 ammonia Inorganic materials 0.000 description 5
• 208000011775 arteriosclerosis disease Diseases 0.000 description 5
• 210000001367 artery Anatomy 0.000 description 5
• 239000000460 chlorine Substances 0.000 description 5
• 238000004587 chromatography analysis Methods 0.000 description 5
• 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 5
• 210000001072 colon Anatomy 0.000 description 5
• 230000003111 delayed effect Effects 0.000 description 5
• 235000014113 dietary fatty acids Nutrition 0.000 description 5
• 239000002270 dispersing agent Substances 0.000 description 5
• 239000000839 emulsion Substances 0.000 description 5
• 239000007920 enema Substances 0.000 description 5
• 210000003979 eosinophil Anatomy 0.000 description 5
• 239000000194 fatty acid Substances 0.000 description 5
• 229930195729 fatty acid Natural products 0.000 description 5
• 239000000499 gel Substances 0.000 description 5
• 150000002367 halogens Chemical class 0.000 description 5
• 125000004404 heteroalkyl group Chemical group 0.000 description 5
• 239000008101 lactose Substances 0.000 description 5
• 239000003446 ligand Substances 0.000 description 5
• 201000000050 myeloid neoplasm Diseases 0.000 description 5
• 231100000252 nontoxic Toxicity 0.000 description 5
• 230000003000 nontoxic effect Effects 0.000 description 5
• 239000003921 oil Substances 0.000 description 5
• 235000019198 oils Nutrition 0.000 description 5
• 235000019271 petrolatum Nutrition 0.000 description 5
• 235000021317 phosphate Nutrition 0.000 description 5
• 239000002244 precipitate Substances 0.000 description 5
• 230000002829 reductive effect Effects 0.000 description 5
• 238000004007 reversed phase HPLC Methods 0.000 description 5
• 239000012266 salt solution Substances 0.000 description 5
• 238000007920 subcutaneous administration Methods 0.000 description 5
• 125000005346 substituted cycloalkyl group Chemical group 0.000 description 5
• 150000003462 sulfoxides Chemical class 0.000 description 5
• 125000004434 sulfur atom Chemical group 0.000 description 5
• 230000009885 systemic effect Effects 0.000 description 5
• 238000011200 topical administration Methods 0.000 description 5
• 230000005945 translocation Effects 0.000 description 5
• MAYZWDRUFKUGGP-VIFPVBQESA-N (3s)-1-[5-tert-butyl-3-[(1-methyltetrazol-5-yl)methyl]triazolo[4,5-d]pyrimidin-7-yl]pyrrolidin-3-ol Chemical compound CN1N=NN=C1CN1C2=NC(C(C)(C)C)=NC(N3C[C@@H](O)CC3)=C2N=N1 MAYZWDRUFKUGGP-VIFPVBQESA-N 0.000 description 4
• PKDPUENCROCRCH-UHFFFAOYSA-N 1-piperazin-1-ylethanone Chemical compound CC(=O)N1CCNCC1 PKDPUENCROCRCH-UHFFFAOYSA-N 0.000 description 4
• HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
• 201000001320 Atherosclerosis Diseases 0.000 description 4
• 241000283690 Bos taurus Species 0.000 description 4
• 241000282472 Canis lupus familiaris Species 0.000 description 4
• 208000024172 Cardiovascular disease Diseases 0.000 description 4
• ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 4
• QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 4
• 241000282326 Felis catus Species 0.000 description 4
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
• 208000021519 Hodgkin lymphoma Diseases 0.000 description 4
• XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
• 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 4
• NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
• JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
• 206010057190 Respiratory tract infections Diseases 0.000 description 4
• 229920002472 Starch Polymers 0.000 description 4
• 208000025317 T-cell and NK-cell neoplasm Diseases 0.000 description 4
• 208000007814 Unstable Angina Diseases 0.000 description 4
• 208000035868 Vascular inflammations Diseases 0.000 description 4
• 206010047249 Venous thrombosis Diseases 0.000 description 4
• 230000001594 aberrant effect Effects 0.000 description 4
• 230000002378 acidificating effect Effects 0.000 description 4
• 230000009471 action Effects 0.000 description 4
• 230000003213 activating effect Effects 0.000 description 4
• 239000004480 active ingredient Substances 0.000 description 4
• 150000001335 aliphatic alkanes Chemical class 0.000 description 4
• 125000003282 alkyl amino group Chemical group 0.000 description 4
• 125000004390 alkyl sulfonyl group Chemical group 0.000 description 4
• 150000001408 amides Chemical class 0.000 description 4
• 208000007502 anemia Diseases 0.000 description 4
• 125000003710 aryl alkyl group Chemical group 0.000 description 4
• 125000004104 aryloxy group Chemical group 0.000 description 4
• 230000017531 blood circulation Effects 0.000 description 4
• 239000000872 buffer Substances 0.000 description 4
• 239000002775 capsule Substances 0.000 description 4
• 230000003197 catalytic effect Effects 0.000 description 4
• 230000010261 cell growth Effects 0.000 description 4
• 235000010980 cellulose Nutrition 0.000 description 4
• 229920002678 cellulose Polymers 0.000 description 4
• 239000001913 cellulose Substances 0.000 description 4
• 230000008859 change Effects 0.000 description 4
• 239000003153 chemical reaction reagent Substances 0.000 description 4
• 125000004093 cyano group Chemical class *C#N 0.000 description 4
• 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 4
• 125000004663 dialkyl amino group Chemical group 0.000 description 4
• 239000003995 emulsifying agent Substances 0.000 description 4
• 229940095399 enema Drugs 0.000 description 4
• 210000002919 epithelial cell Anatomy 0.000 description 4
• SRJBDGLSCPDXBL-UHFFFAOYSA-N ethyl 2,4-dichloropyrimidine-5-carboxylate Chemical compound CCOC(=O)C1=CN=C(Cl)N=C1Cl SRJBDGLSCPDXBL-UHFFFAOYSA-N 0.000 description 4
• 238000001914 filtration Methods 0.000 description 4
• 230000012010 growth Effects 0.000 description 4
• 125000004474 heteroalkylene group Chemical group 0.000 description 4
• BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 4
• 229960003444 immunosuppressant agent Drugs 0.000 description 4
• 239000003018 immunosuppressive agent Substances 0.000 description 4
• 230000002757 inflammatory effect Effects 0.000 description 4
• 238000001802 infusion Methods 0.000 description 4
• 108010044426 integrins Proteins 0.000 description 4
• 102000006495 integrins Human genes 0.000 description 4
• 238000007918 intramuscular administration Methods 0.000 description 4
• 150000002500 ions Chemical class 0.000 description 4
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 4
• 239000000314 lubricant Substances 0.000 description 4
• 208000019420 lymphoid neoplasm Diseases 0.000 description 4
• 235000019359 magnesium stearate Nutrition 0.000 description 4
• 239000002480 mineral oil Substances 0.000 description 4
• 235000010446 mineral oil Nutrition 0.000 description 4
• 230000007935 neutral effect Effects 0.000 description 4
• 239000002674 ointment Substances 0.000 description 4
• 150000007524 organic acids Chemical class 0.000 description 4
• 125000004430 oxygen atom Chemical group O* 0.000 description 4
• 238000007911 parenteral administration Methods 0.000 description 4
• 239000012071 phase Substances 0.000 description 4
• XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 4
• MXXWOMGUGJBKIW-YPCIICBESA-N piperine Chemical compound C=1C=C2OCOC2=CC=1/C=C/C=C/C(=O)N1CCCCC1 MXXWOMGUGJBKIW-YPCIICBESA-N 0.000 description 4
• 229940075559 piperine Drugs 0.000 description 4
• WVWHRXVVAYXKDE-UHFFFAOYSA-N piperine Natural products O=C(C=CC=Cc1ccc2OCOc2c1)C3CCCCN3 WVWHRXVVAYXKDE-UHFFFAOYSA-N 0.000 description 4
• 235000019100 piperine Nutrition 0.000 description 4
• 238000002953 preparative HPLC Methods 0.000 description 4
• YAAWASYJIRZXSZ-UHFFFAOYSA-N pyrimidine-2,4-diamine Chemical class NC1=CC=NC(N)=N1 YAAWASYJIRZXSZ-UHFFFAOYSA-N 0.000 description 4
• ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 4
• 125000006413 ring segment Chemical group 0.000 description 4
• QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 4
• 229960002930 sirolimus Drugs 0.000 description 4
• 210000003491 skin Anatomy 0.000 description 4
• 235000019698 starch Nutrition 0.000 description 4
• 239000000829 suppository Substances 0.000 description 4
• 239000000375 suspending agent Substances 0.000 description 4
• 201000000596 systemic lupus erythematosus Diseases 0.000 description 4
• 238000012360 testing method Methods 0.000 description 4
• 238000002560 therapeutic procedure Methods 0.000 description 4
• 238000004809 thin layer chromatography Methods 0.000 description 4
• 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 4
• XJPZKYIHCLDXST-UHFFFAOYSA-N 4,6-dichloropyrimidine Chemical compound ClC1=CC(Cl)=NC=N1 XJPZKYIHCLDXST-UHFFFAOYSA-N 0.000 description 3
• UFDPHYCBZZENCG-UHFFFAOYSA-N 4-(2h-benzotriazol-4-yloxy)-2h-benzotriazole Chemical compound C1=CC2=NNN=C2C(OC=2C3=NNN=C3C=CC=2)=C1 UFDPHYCBZZENCG-UHFFFAOYSA-N 0.000 description 3
• JXRGUPLJCCDGKG-UHFFFAOYSA-N 4-nitrobenzenesulfonyl chloride Chemical compound [O-][N+](=O)C1=CC=C(S(Cl)(=O)=O)C=C1 JXRGUPLJCCDGKG-UHFFFAOYSA-N 0.000 description 3
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
• WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
• CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
• 208000004476 Acute Coronary Syndrome Diseases 0.000 description 3
• 108700028369 Alleles Proteins 0.000 description 3
• 206010002383 Angina Pectoris Diseases 0.000 description 3
• DCERHCFNWRGHLK-UHFFFAOYSA-N C[Si](C)C Chemical compound C[Si](C)C DCERHCFNWRGHLK-UHFFFAOYSA-N 0.000 description 3
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
• 241000283707 Capra Species 0.000 description 3
• 208000031404 Chromosome Aberrations Diseases 0.000 description 3
• 206010009900 Colitis ulcerative Diseases 0.000 description 3
• PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 3
• 108010036949 Cyclosporine Proteins 0.000 description 3
• 208000006313 Delayed Hypersensitivity Diseases 0.000 description 3
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
• 206010058314 Dysplasia Diseases 0.000 description 3
• 241000283086 Equidae Species 0.000 description 3
• 108010010803 Gelatin Proteins 0.000 description 3
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
• 206010061187 Haematopoietic neoplasm Diseases 0.000 description 3
• 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 3
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
• 239000012359 Methanesulfonyl chloride Substances 0.000 description 3
• 241001529936 Murinae Species 0.000 description 3
• 241000283973 Oryctolagus cuniculus Species 0.000 description 3
• 241001494479 Pecora Species 0.000 description 3
• 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 3
• RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
• 229930006000 Sucrose Natural products 0.000 description 3
• 241000282887 Suidae Species 0.000 description 3
• QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 3
• 201000006704 Ulcerative Colitis Diseases 0.000 description 3
• 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 3
• 229910052784 alkaline earth metal Inorganic materials 0.000 description 3
• 208000026935 allergic disease Diseases 0.000 description 3
• 230000000172 allergic effect Effects 0.000 description 3
• 125000003277 amino group Chemical group 0.000 description 3
• 238000002399 angioplasty Methods 0.000 description 3
• 125000005161 aryl oxy carbonyl group Chemical group 0.000 description 3
• 230000003143 atherosclerotic effect Effects 0.000 description 3
• 208000010668 atopic eczema Diseases 0.000 description 3
• 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 3
• 229960002170 azathioprine Drugs 0.000 description 3
• LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 3
• 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 3
• 230000008901 benefit Effects 0.000 description 3
• HDCIPVZAKAAPAU-UHFFFAOYSA-N benzyl 3-[[[2-[4-(4-acetylpiperazin-1-yl)anilino]-5-carbamoylpyrimidin-4-yl]amino]methyl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1NC1=NC=C(C(N)=O)C(NCC2CN(CCC2)C(=O)OCC=2C=CC=CC=2)=N1 HDCIPVZAKAAPAU-UHFFFAOYSA-N 0.000 description 3
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
• 210000002798 bone marrow cell Anatomy 0.000 description 3
• GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
• 229910052794 bromium Inorganic materials 0.000 description 3
• 239000011575 calcium Substances 0.000 description 3
• 229910052791 calcium Inorganic materials 0.000 description 3
• 230000002612 cardiopulmonary effect Effects 0.000 description 3
• 230000032823 cell division Effects 0.000 description 3
• 230000036755 cellular response Effects 0.000 description 3
• 210000003169 central nervous system Anatomy 0.000 description 3
• 229960001265 ciclosporin Drugs 0.000 description 3
• 238000007887 coronary angioplasty Methods 0.000 description 3
• 239000006071 cream Substances 0.000 description 3
• 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
• UKJLNMAFNRKWGR-UHFFFAOYSA-N cyclohexatrienamine Chemical group NC1=CC=C=C[CH]1 UKJLNMAFNRKWGR-UHFFFAOYSA-N 0.000 description 3
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
• IGSKHXTUVXSOMB-UHFFFAOYSA-N cyclopropylmethanamine Chemical compound NCC1CC1 IGSKHXTUVXSOMB-UHFFFAOYSA-N 0.000 description 3
• 229930182912 cyclosporin Natural products 0.000 description 3
• 108010057085 cytokine receptors Proteins 0.000 description 3
• 102000003675 cytokine receptors Human genes 0.000 description 3
• 231100000433 cytotoxic Toxicity 0.000 description 3
• 230000001472 cytotoxic effect Effects 0.000 description 3
• 230000034994 death Effects 0.000 description 3
• 230000003247 decreasing effect Effects 0.000 description 3
• UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
• 210000003743 erythrocyte Anatomy 0.000 description 3
• 125000004494 ethyl ester group Chemical group 0.000 description 3
• 201000003444 follicular lymphoma Diseases 0.000 description 3
• 230000005714 functional activity Effects 0.000 description 3
• 210000001035 gastrointestinal tract Anatomy 0.000 description 3
• 239000008273 gelatin Substances 0.000 description 3
• 229920000159 gelatin Polymers 0.000 description 3
• 229940014259 gelatin Drugs 0.000 description 3
• 235000019322 gelatine Nutrition 0.000 description 3
• 235000011852 gelatine desserts Nutrition 0.000 description 3
• 239000008187 granular material Substances 0.000 description 3
• 201000005787 hematologic cancer Diseases 0.000 description 3
• 208000007475 hemolytic anemia Diseases 0.000 description 3
• 229930195733 hydrocarbon Natural products 0.000 description 3
• 238000005984 hydrogenation reaction Methods 0.000 description 3
• 238000006460 hydrolysis reaction Methods 0.000 description 3
• 230000001861 immunosuppressant effect Effects 0.000 description 3
• 238000002650 immunosuppressive therapy Methods 0.000 description 3
• 230000006872 improvement Effects 0.000 description 3
• 238000007912 intraperitoneal administration Methods 0.000 description 3
• 229910052740 iodine Inorganic materials 0.000 description 3
• 125000005647 linker group Chemical group 0.000 description 3
• 239000006210 lotion Substances 0.000 description 3
• 206010025135 lupus erythematosus Diseases 0.000 description 3
• 208000003747 lymphoid leukemia Diseases 0.000 description 3
• 230000003211 malignant effect Effects 0.000 description 3
• 239000012528 membrane Substances 0.000 description 3
• QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 3
• HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 3
• 150000007522 mineralic acids Chemical class 0.000 description 3
• 230000004048 modification Effects 0.000 description 3
• 238000012986 modification Methods 0.000 description 3
• 150000004682 monohydrates Chemical class 0.000 description 3
• RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 3
• 229960004866 mycophenolate mofetil Drugs 0.000 description 3
• HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 3
• VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
• 235000005985 organic acids Nutrition 0.000 description 3
• 150000007530 organic bases Chemical class 0.000 description 3
• AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 3
• 230000002093 peripheral effect Effects 0.000 description 3
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
• 239000010452 phosphate Substances 0.000 description 3
• HDOWRFHMPULYOA-UHFFFAOYSA-N piperidin-4-ol Chemical compound OC1CCNCC1 HDOWRFHMPULYOA-UHFFFAOYSA-N 0.000 description 3
• DNUTZBZXLPWRJG-UHFFFAOYSA-M piperidine-1-carboxylate Chemical compound [O-]C(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-M 0.000 description 3
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
• 239000003755 preservative agent Substances 0.000 description 3
• RZWZRACFZGVKFM-UHFFFAOYSA-N propanoyl chloride Chemical compound CCC(Cl)=O RZWZRACFZGVKFM-UHFFFAOYSA-N 0.000 description 3
• UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical compound OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 description 3
• 230000009467 reduction Effects 0.000 description 3
• 238000012216 screening Methods 0.000 description 3
• 238000000926 separation method Methods 0.000 description 3
• 239000000741 silica gel Substances 0.000 description 3
• 229910002027 silica gel Inorganic materials 0.000 description 3
• 229910052708 sodium Inorganic materials 0.000 description 3
• 239000008107 starch Substances 0.000 description 3
• 239000000758 substrate Substances 0.000 description 3
• 239000005720 sucrose Substances 0.000 description 3
• 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 3
• 239000004094 surface-active agent Substances 0.000 description 3
• 238000013268 sustained release Methods 0.000 description 3
• 239000012730 sustained-release form Substances 0.000 description 3
• 229960001967 tacrolimus Drugs 0.000 description 3
• QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 3
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
• 238000013518 transcription Methods 0.000 description 3
• 230000035897 transcription Effects 0.000 description 3
• 230000007704 transition Effects 0.000 description 3
• 201000008827 tuberculosis Diseases 0.000 description 3
• 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 3
• 239000001993 wax Substances 0.000 description 3
• PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
• PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 2
• 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
• KEJFADGISRFLFO-UHFFFAOYSA-N 1H-indazol-6-amine Chemical compound NC1=CC=C2C=NNC2=C1 KEJFADGISRFLFO-UHFFFAOYSA-N 0.000 description 2
• OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 2
• NWSQMSSJOTZBLY-UHFFFAOYSA-N 2-[4-(4-acetylpiperazin-1-yl)anilino]-4-(piperidin-3-ylmethylamino)pyrimidine-5-carboxamide Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1NC1=NC=C(C(N)=O)C(NCC2CNCCC2)=N1 NWSQMSSJOTZBLY-UHFFFAOYSA-N 0.000 description 2
• NDQROJWWYNXXBY-UHFFFAOYSA-N 2-[4-(4-acetylpiperazin-1-yl)anilino]-4-(piperidin-4-ylmethylamino)pyrimidine-5-carboxamide Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1NC1=NC=C(C(N)=O)C(NCC2CCNCC2)=N1 NDQROJWWYNXXBY-UHFFFAOYSA-N 0.000 description 2
• NTZAWXGXAHWRHB-UHFFFAOYSA-N 2-chloro-4-[(1-methylindol-4-yl)amino]pyrimidine-5-carboxylic acid Chemical compound C1=CC=C2N(C)C=CC2=C1NC1=NC(Cl)=NC=C1C(O)=O NTZAWXGXAHWRHB-UHFFFAOYSA-N 0.000 description 2
• NWWCSEYOUUEBFS-UHFFFAOYSA-N 2-chloro-4-[(1-phenylmethoxycarbonylpiperidin-3-yl)methylamino]pyrimidine-5-carboxylic acid Chemical compound OC(=O)C1=CN=C(Cl)N=C1NCC1CN(C(=O)OCC=2C=CC=CC=2)CCC1 NWWCSEYOUUEBFS-UHFFFAOYSA-N 0.000 description 2
• TZAUNSMCTPHZDF-UHFFFAOYSA-N 2-chloro-4-[[1-[(2-methylpropan-2-yl)oxycarbonyl]piperidin-4-yl]methylamino]pyrimidine-5-carboxylic acid Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1CNC1=NC(Cl)=NC=C1C(O)=O TZAUNSMCTPHZDF-UHFFFAOYSA-N 0.000 description 2
• LOCWBQIWHWIRGN-UHFFFAOYSA-N 2-chloro-4-nitroaniline Chemical compound NC1=CC=C([N+]([O-])=O)C=C1Cl LOCWBQIWHWIRGN-UHFFFAOYSA-N 0.000 description 2
• ASUDFOJKTJLAIK-UHFFFAOYSA-N 2-methoxyethanamine Chemical compound COCCN ASUDFOJKTJLAIK-UHFFFAOYSA-N 0.000 description 2
• UOGQPXQDNUHUIB-UHFFFAOYSA-N 3,3-difluoropiperidine Chemical compound FC1(F)CCCNC1 UOGQPXQDNUHUIB-UHFFFAOYSA-N 0.000 description 2
• KVTUSMPNLUCCQO-UHFFFAOYSA-N 3,3-difluoropyrrolidine Chemical compound FC1(F)CCNC1 KVTUSMPNLUCCQO-UHFFFAOYSA-N 0.000 description 2
• MKARNSWMMBGSHX-UHFFFAOYSA-N 3,5-dimethylaniline Chemical compound CC1=CC(C)=CC(N)=C1 MKARNSWMMBGSHX-UHFFFAOYSA-N 0.000 description 2
• SRVXSISGYBMIHR-UHFFFAOYSA-N 3-[3-[3-(2-amino-2-oxoethyl)phenyl]-5-chlorophenyl]-3-(5-methyl-1,3-thiazol-2-yl)propanoic acid Chemical compound S1C(C)=CN=C1C(CC(O)=O)C1=CC(Cl)=CC(C=2C=C(CC(N)=O)C=CC=2)=C1 SRVXSISGYBMIHR-UHFFFAOYSA-N 0.000 description 2
• NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 2
• MJOUJKDTBGXKIU-UHFFFAOYSA-N 4,4-difluoropiperidine Chemical compound FC1(F)CCNCC1 MJOUJKDTBGXKIU-UHFFFAOYSA-N 0.000 description 2
• XUJFOSLZQITUOI-UHFFFAOYSA-N 4-(trifluoromethoxy)aniline Chemical compound NC1=CC=C(OC(F)(F)F)C=C1 XUJFOSLZQITUOI-UHFFFAOYSA-N 0.000 description 2
• QIKYZXDTTPVVAC-UHFFFAOYSA-N 4-Aminobenzamide Chemical compound NC(=O)C1=CC=C(N)C=C1 QIKYZXDTTPVVAC-UHFFFAOYSA-N 0.000 description 2
• TZUPESZOLNEHAJ-UHFFFAOYSA-N 4-[(1-methylindol-4-yl)amino]-2-[4-(2-pyrrolidin-1-ylethoxy)anilino]pyrimidine-5-carboxamide Chemical compound C1=CC=C2N(C)C=CC2=C1NC(C(=CN=1)C(N)=O)=NC=1NC(C=C1)=CC=C1OCCN1CCCC1 TZUPESZOLNEHAJ-UHFFFAOYSA-N 0.000 description 2
• IMPPGHMHELILKG-UHFFFAOYSA-N 4-ethoxyaniline Chemical compound CCOC1=CC=C(N)C=C1 IMPPGHMHELILKG-UHFFFAOYSA-N 0.000 description 2
• QBLLOOKBLTTXHB-UHFFFAOYSA-N 4-fluoropiperidine Chemical compound FC1CCNCC1 QBLLOOKBLTTXHB-UHFFFAOYSA-N 0.000 description 2
• WOYZXEVUWXQVNV-UHFFFAOYSA-N 4-phenoxyaniline Chemical compound C1=CC(N)=CC=C1OC1=CC=CC=C1 WOYZXEVUWXQVNV-UHFFFAOYSA-N 0.000 description 2
• ZSLIXJKSPVCNHZ-UHFFFAOYSA-N 4-pyridin-3-yloxyaniline Chemical compound C1=CC(N)=CC=C1OC1=CC=CN=C1 ZSLIXJKSPVCNHZ-UHFFFAOYSA-N 0.000 description 2
• ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
• 244000215068 Acacia senegal Species 0.000 description 2
• 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 2
• 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
• NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
• QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
• 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 description 2
• 206010002388 Angina unstable Diseases 0.000 description 2
• 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 2
• 102000001381 Arachidonate 5-Lipoxygenase Human genes 0.000 description 2
• 108010093579 Arachidonate 5-lipoxygenase Proteins 0.000 description 2
• 239000004475 Arginine Substances 0.000 description 2
• 208000004300 Atrophic Gastritis Diseases 0.000 description 2
• 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 2
• 208000033222 Biliary cirrhosis primary Diseases 0.000 description 2
• 241000283725 Bos Species 0.000 description 2
• 208000033386 Buerger disease Diseases 0.000 description 2
• 208000011691 Burkitt lymphomas Diseases 0.000 description 2
• 239000004215 Carbon black (E152) Substances 0.000 description 2
• 102000003952 Caspase 3 Human genes 0.000 description 2
• 108090000397 Caspase 3 Proteins 0.000 description 2
• 241000282693 Cercopithecidae Species 0.000 description 2
• 206010008190 Cerebrovascular accident Diseases 0.000 description 2
• 108091006146 Channels Proteins 0.000 description 2
• 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 2
• 208000032544 Cicatrix Diseases 0.000 description 2
• 206010053567 Coagulopathies Diseases 0.000 description 2
• 206010056370 Congestive cardiomyopathy Diseases 0.000 description 2
• 229920002261 Corn starch Polymers 0.000 description 2
• 206010011091 Coronary artery thrombosis Diseases 0.000 description 2
• 229930105110 Cyclosporin A Natural products 0.000 description 2
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
• 206010051055 Deep vein thrombosis Diseases 0.000 description 2
• 201000010046 Dilated cardiomyopathy Diseases 0.000 description 2
• LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
• 108090000204 Dipeptidase 1 Proteins 0.000 description 2
• 208000005189 Embolism Diseases 0.000 description 2
• 208000004248 Familial Primary Pulmonary Hypertension Diseases 0.000 description 2
• 206010016654 Fibrosis Diseases 0.000 description 2
• PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
• 206010017533 Fungal infection Diseases 0.000 description 2
• 208000036495 Gastritis atrophic Diseases 0.000 description 2
• 208000034951 Genetic Translocation Diseases 0.000 description 2
• 108010044091 Globulins Proteins 0.000 description 2
• 102000006395 Globulins Human genes 0.000 description 2
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
• 229920000084 Gum arabic Polymers 0.000 description 2
• 208000030836 Hashimoto thyroiditis Diseases 0.000 description 2
• 208000028782 Hereditary disease Diseases 0.000 description 2
• NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
• 241000725303 Human immunodeficiency virus Species 0.000 description 2
• 208000028622 Immune thrombocytopenia Diseases 0.000 description 2
• 108060003951 Immunoglobulin Proteins 0.000 description 2
• 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
• 102000008070 Interferon-gamma Human genes 0.000 description 2
• 108010074328 Interferon-gamma Proteins 0.000 description 2
• 102000015617 Janus Kinases Human genes 0.000 description 2
• 108010024121 Janus Kinases Proteins 0.000 description 2
• 208000008839 Kidney Neoplasms Diseases 0.000 description 2
• ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
• KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
• 208000032004 Large-Cell Anaplastic Lymphoma Diseases 0.000 description 2
• 208000019693 Lung disease Diseases 0.000 description 2
• 208000028018 Lymphocytic leukaemia Diseases 0.000 description 2
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
• 239000004472 Lysine Substances 0.000 description 2
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
• 229930195725 Mannitol Natural products 0.000 description 2
• 208000035490 Megakaryoblastic Acute Leukemia Diseases 0.000 description 2
• FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 2
• 241000699666 Mus <mouse, genus> Species 0.000 description 2
• 101001081106 Mus musculus Helicase-like transcription factor Proteins 0.000 description 2
• 208000014767 Myeloproliferative disease Diseases 0.000 description 2
• LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
• MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
• KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
• 208000031481 Pathologic Constriction Diseases 0.000 description 2
• 239000004264 Petrolatum Substances 0.000 description 2
• 206010057249 Phagocytosis Diseases 0.000 description 2
• GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
• 208000012654 Primary biliary cholangitis Diseases 0.000 description 2
• 206010064911 Pulmonary arterial hypertension Diseases 0.000 description 2
• 241000700159 Rattus Species 0.000 description 2
• 208000009527 Refractory anemia Diseases 0.000 description 2
• 206010072684 Refractory cytopenia with unilineage dysplasia Diseases 0.000 description 2
• 208000033464 Reiter syndrome Diseases 0.000 description 2
• 206010038389 Renal cancer Diseases 0.000 description 2
• 108010016797 Sickle Hemoglobin Proteins 0.000 description 2
• CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
• PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
• UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
• 229920002125 Sokalan® Polymers 0.000 description 2
• 201000009594 Systemic Scleroderma Diseases 0.000 description 2
• 206010042953 Systemic sclerosis Diseases 0.000 description 2
• 230000006044 T cell activation Effects 0.000 description 2
• 108091008874 T cell receptors Proteins 0.000 description 2
• 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
• 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 2
• 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 2
• 208000002903 Thalassemia Diseases 0.000 description 2
• 206010043540 Thromboangiitis obliterans Diseases 0.000 description 2
• 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 2
• 201000007023 Thrombotic Thrombocytopenic Purpura Diseases 0.000 description 2
• 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
• 102000014384 Type C Phospholipases Human genes 0.000 description 2
• 108010079194 Type C Phospholipases Proteins 0.000 description 2
• 206010054000 Type II hypersensitivity Diseases 0.000 description 2
• 206010053614 Type III immune complex mediated reaction Diseases 0.000 description 2
• XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical class NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
• 206010052664 Vascular shunt Diseases 0.000 description 2
• 206010047115 Vasculitis Diseases 0.000 description 2
• 235000010489 acacia gum Nutrition 0.000 description 2
• 239000000205 acacia gum Substances 0.000 description 2
• 230000035508 accumulation Effects 0.000 description 2
• 238000009825 accumulation Methods 0.000 description 2
• 150000007513 acids Chemical class 0.000 description 2
• 208000013593 acute megakaryoblastic leukemia Diseases 0.000 description 2
• 208000020700 acute megakaryocytic leukemia Diseases 0.000 description 2
• 125000004442 acylamino group Chemical group 0.000 description 2
• 125000004423 acyloxy group Chemical group 0.000 description 2
• 239000002671 adjuvant Substances 0.000 description 2
• 230000002776 aggregation Effects 0.000 description 2
• 238000004220 aggregation Methods 0.000 description 2
• 230000008484 agonism Effects 0.000 description 2
• 235000010443 alginic acid Nutrition 0.000 description 2
• 229920000615 alginic acid Polymers 0.000 description 2
• 125000000033 alkoxyamino group Chemical group 0.000 description 2
• 125000003806 alkyl carbonyl amino group Chemical group 0.000 description 2
• 125000004414 alkyl thio group Chemical group 0.000 description 2
• 125000005133 alkynyloxy group Chemical group 0.000 description 2
• 239000013566 allergen Substances 0.000 description 2
• 239000003708 ampul Substances 0.000 description 2
• 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
• 230000002052 anaphylactic effect Effects 0.000 description 2
• 238000010171 animal model Methods 0.000 description 2
• 230000008485 antagonism Effects 0.000 description 2
• 239000003146 anticoagulant agent Substances 0.000 description 2
• 239000007864 aqueous solution Substances 0.000 description 2
• YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
• 206010003230 arteritis Diseases 0.000 description 2
• 125000001769 aryl amino group Chemical group 0.000 description 2
• 125000005110 aryl thio group Chemical group 0.000 description 2
• 208000010216 atopic IgE responsiveness Diseases 0.000 description 2
• 210000003651 basophil Anatomy 0.000 description 2
• 125000005605 benzo group Chemical group 0.000 description 2
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
• 235000019445 benzyl alcohol Nutrition 0.000 description 2
• WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
• 125000002619 bicyclic group Chemical group 0.000 description 2
• 239000011230 binding agent Substances 0.000 description 2
• 230000000903 blocking effect Effects 0.000 description 2
• 230000023555 blood coagulation Effects 0.000 description 2
• 208000015294 blood coagulation disease Diseases 0.000 description 2
• 210000001185 bone marrow Anatomy 0.000 description 2
• 150000001649 bromium compounds Chemical class 0.000 description 2
• 206010006451 bronchitis Diseases 0.000 description 2
• RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
• 239000001506 calcium phosphate Substances 0.000 description 2
• 125000005518 carboxamido group Chemical group 0.000 description 2
• 239000001768 carboxy methyl cellulose Substances 0.000 description 2
• 230000004663 cell proliferation Effects 0.000 description 2
• 230000007969 cellular immunity Effects 0.000 description 2
• 208000026106 cerebrovascular disease Diseases 0.000 description 2
• 239000012320 chlorinating reagent Substances 0.000 description 2
• 229910052801 chlorine Inorganic materials 0.000 description 2
• 231100000005 chromosome aberration Toxicity 0.000 description 2
• 208000016644 chronic atrophic gastritis Diseases 0.000 description 2
• 208000020832 chronic kidney disease Diseases 0.000 description 2
• 238000003776 cleavage reaction Methods 0.000 description 2
• 238000000576 coating method Methods 0.000 description 2
• 238000002648 combination therapy Methods 0.000 description 2
• 238000007796 conventional method Methods 0.000 description 2
• 239000008120 corn starch Substances 0.000 description 2
• 208000029078 coronary artery disease Diseases 0.000 description 2
• 208000002528 coronary thrombosis Diseases 0.000 description 2
• 238000004132 cross linking Methods 0.000 description 2
• AUELWJRRASQDKI-UHFFFAOYSA-N cyclohexyl carbamate Chemical compound NC(=O)OC1CCCCC1 AUELWJRRASQDKI-UHFFFAOYSA-N 0.000 description 2
• 125000006312 cyclopentyl amino group Chemical group [H]N(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
• 230000001086 cytosolic effect Effects 0.000 description 2
• 230000007423 decrease Effects 0.000 description 2
• 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
• 230000002950 deficient Effects 0.000 description 2
• 238000012217 deletion Methods 0.000 description 2
• 230000037430 deletion Effects 0.000 description 2
• 230000008021 deposition Effects 0.000 description 2
• 201000001981 dermatomyositis Diseases 0.000 description 2
• 239000008121 dextrose Substances 0.000 description 2
• 125000005117 dialkylcarbamoyl group Chemical group 0.000 description 2
• ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
• 239000007884 disintegrant Substances 0.000 description 2
• 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
• 230000002526 effect on cardiovascular system Effects 0.000 description 2
• 201000002491 encephalomyelitis Diseases 0.000 description 2
• 208000028208 end stage renal disease Diseases 0.000 description 2
• 201000000523 end stage renal failure Diseases 0.000 description 2
• 239000003623 enhancer Substances 0.000 description 2
• 230000002255 enzymatic effect Effects 0.000 description 2
• XKDBEILSWOIJQY-UHFFFAOYSA-N ethyl 2-chloro-4-[[1-[(2-methylpropan-2-yl)oxycarbonyl]piperidin-4-yl]methylamino]pyrimidine-5-carboxylate Chemical compound CCOC(=O)C1=CN=C(Cl)N=C1NCC1CCN(C(=O)OC(C)(C)C)CC1 XKDBEILSWOIJQY-UHFFFAOYSA-N 0.000 description 2
• 230000029142 excretion Effects 0.000 description 2
• 235000019197 fats Nutrition 0.000 description 2
• 150000004665 fatty acids Chemical class 0.000 description 2
• 230000004761 fibrosis Effects 0.000 description 2
• 239000000706 filtrate Substances 0.000 description 2
• 238000003818 flash chromatography Methods 0.000 description 2
• 229910052731 fluorine Inorganic materials 0.000 description 2
• 239000011737 fluorine Substances 0.000 description 2
• 230000003325 follicular Effects 0.000 description 2
• 238000004108 freeze drying Methods 0.000 description 2
• 208000024386 fungal infectious disease Diseases 0.000 description 2
• 125000005456 glyceride group Chemical group 0.000 description 2
• 235000011187 glycerol Nutrition 0.000 description 2
• KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
• 239000003102 growth factor Substances 0.000 description 2
• 230000003394 haemopoietic effect Effects 0.000 description 2
• 210000003709 heart valve Anatomy 0.000 description 2
• 208000006454 hepatitis Diseases 0.000 description 2
• 231100000283 hepatitis Toxicity 0.000 description 2
• 230000028996 humoral immune response Effects 0.000 description 2
• WJRBRSLFGCUECM-UHFFFAOYSA-N hydantoin Chemical compound O=C1CNC(=O)N1 WJRBRSLFGCUECM-UHFFFAOYSA-N 0.000 description 2
• 150000002430 hydrocarbons Chemical group 0.000 description 2
• 229910000042 hydrogen bromide Inorganic materials 0.000 description 2
• 230000007062 hydrolysis Effects 0.000 description 2
• 125000002349 hydroxyamino group Chemical group [H]ON([H])[*] 0.000 description 2
• 230000009610 hypersensitivity Effects 0.000 description 2
• 150000002466 imines Chemical class 0.000 description 2
• 210000002865 immune cell Anatomy 0.000 description 2
• 230000028993 immune response Effects 0.000 description 2
• 102000018358 immunoglobulin Human genes 0.000 description 2
• 239000012442 inert solvent Substances 0.000 description 2
• 238000003780 insertion Methods 0.000 description 2
• 230000037431 insertion Effects 0.000 description 2
• 230000003993 interaction Effects 0.000 description 2
• 229960003130 interferon gamma Drugs 0.000 description 2
• 201000004332 intermediate coronary syndrome Diseases 0.000 description 2
• 238000001361 intraarterial administration Methods 0.000 description 2
• 238000007914 intraventricular administration Methods 0.000 description 2
• 150000004694 iodide salts Chemical class 0.000 description 2
• 229910052742 iron Inorganic materials 0.000 description 2
• 208000002551 irritable bowel syndrome Diseases 0.000 description 2
• 208000028867 ischemia Diseases 0.000 description 2
• SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
• 238000005304 joining Methods 0.000 description 2
• 201000010982 kidney cancer Diseases 0.000 description 2
• 229940043355 kinase inhibitor Drugs 0.000 description 2
• ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 2
• GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium;hydroxide;hydrate Chemical compound [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 2
• NCBZRJODKRCREW-UHFFFAOYSA-N m-anisidine Chemical compound COC1=CC=CC(N)=C1 NCBZRJODKRCREW-UHFFFAOYSA-N 0.000 description 2
• 239000011777 magnesium Substances 0.000 description 2
• 229910052749 magnesium Inorganic materials 0.000 description 2
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
• 230000036210 malignancy Effects 0.000 description 2
• 210000004962 mammalian cell Anatomy 0.000 description 2
• 239000000594 mannitol Substances 0.000 description 2
• 235000010355 mannitol Nutrition 0.000 description 2
• 230000000873 masking effect Effects 0.000 description 2
• 239000000463 material Substances 0.000 description 2
• 230000007246 mechanism Effects 0.000 description 2
• GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical class S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
• 230000004060 metabolic process Effects 0.000 description 2
• BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
• 229960000485 methotrexate Drugs 0.000 description 2
• ZKGGELKXEUSJSA-UHFFFAOYSA-N methyl n-(4-aminophenyl)-n-methylcarbamate Chemical compound COC(=O)N(C)C1=CC=C(N)C=C1 ZKGGELKXEUSJSA-UHFFFAOYSA-N 0.000 description 2
• 229960004584 methylprednisolone Drugs 0.000 description 2
• 238000002156 mixing Methods 0.000 description 2
• 239000003607 modifier Substances 0.000 description 2
• 210000001616 monocyte Anatomy 0.000 description 2
• 238000000465 moulding Methods 0.000 description 2
• 229940014456 mycophenolate Drugs 0.000 description 2
• 208000017869 myelodysplastic/myeloproliferative disease Diseases 0.000 description 2
• 230000000926 neurological effect Effects 0.000 description 2
• 210000000440 neutrophil Anatomy 0.000 description 2
• 239000000346 nonvolatile oil Substances 0.000 description 2
• 238000006384 oligomerization reaction Methods 0.000 description 2
• 239000004006 olive oil Substances 0.000 description 2
• 235000008390 olive oil Nutrition 0.000 description 2
• 231100000590 oncogenic Toxicity 0.000 description 2
• 230000002246 oncogenic effect Effects 0.000 description 2
• 201000005737 orchitis Diseases 0.000 description 2
• 201000008482 osteoarthritis Diseases 0.000 description 2
• BHAAPTBBJKJZER-UHFFFAOYSA-N p-anisidine Chemical compound COC1=CC=C(N)C=C1 BHAAPTBBJKJZER-UHFFFAOYSA-N 0.000 description 2
• NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
• 210000000496 pancreas Anatomy 0.000 description 2
• 230000036961 partial effect Effects 0.000 description 2
• 230000007170 pathology Effects 0.000 description 2
• 229940066842 petrolatum Drugs 0.000 description 2
• 230000008782 phagocytosis Effects 0.000 description 2
• 229940124531 pharmaceutical excipient Drugs 0.000 description 2
• 150000003013 phosphoric acid derivatives Chemical class 0.000 description 2
• 239000003757 phosphotransferase inhibitor Substances 0.000 description 2
• 239000006187 pill Substances 0.000 description 2
• 230000010118 platelet activation Effects 0.000 description 2
• 125000003367 polycyclic group Chemical group 0.000 description 2
• 229920000642 polymer Polymers 0.000 description 2
• 229920001451 polypropylene glycol Polymers 0.000 description 2
• 229960005205 prednisolone Drugs 0.000 description 2
• OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 2
• XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 2
• 229960004618 prednisone Drugs 0.000 description 2
• 230000002265 prevention Effects 0.000 description 2
• 201000008312 primary pulmonary hypertension Diseases 0.000 description 2
• 230000001737 promoting effect Effects 0.000 description 2
• JKANAVGODYYCQF-UHFFFAOYSA-N prop-2-yn-1-amine Chemical compound NCC#C JKANAVGODYYCQF-UHFFFAOYSA-N 0.000 description 2
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
• WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 2
• 239000002599 prostaglandin synthase inhibitor Substances 0.000 description 2
• 230000002685 pulmonary effect Effects 0.000 description 2
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
• 230000005855 radiation Effects 0.000 description 2
• 230000002285 radioactive effect Effects 0.000 description 2
• 208000002574 reactive arthritis Diseases 0.000 description 2
• 238000011084 recovery Methods 0.000 description 2
• 230000007115 recruitment Effects 0.000 description 2
• 230000000306 recurrent effect Effects 0.000 description 2
• 230000001105 regulatory effect Effects 0.000 description 2
• 230000002441 reversible effect Effects 0.000 description 2
• 231100000241 scar Toxicity 0.000 description 2
• 230000037387 scars Effects 0.000 description 2
• 230000007017 scission Effects 0.000 description 2
• 230000028327 secretion Effects 0.000 description 2
• QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
• RMBAVIFYHOYIFM-UHFFFAOYSA-M sodium methanethiolate Chemical compound [Na+].[S-]C RMBAVIFYHOYIFM-UHFFFAOYSA-M 0.000 description 2
• LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
• 239000000600 sorbitol Substances 0.000 description 2
• 235000010356 sorbitol Nutrition 0.000 description 2
• 239000007921 spray Substances 0.000 description 2
• 239000003381 stabilizer Substances 0.000 description 2
• 230000036262 stenosis Effects 0.000 description 2
• 208000037804 stenosis Diseases 0.000 description 2
• FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 2
• 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 2
• 229940124530 sulfonamide Drugs 0.000 description 2
• 125000006296 sulfonyl amino group Chemical group [H]N(*)S(*)(=O)=O 0.000 description 2
• 239000003765 sweetening agent Substances 0.000 description 2
• 239000006188 syrup Substances 0.000 description 2
• 235000020357 syrup Nutrition 0.000 description 2
• 239000000454 talc Substances 0.000 description 2
• 229910052623 talc Inorganic materials 0.000 description 2
• 235000012222 talc Nutrition 0.000 description 2
• 230000008685 targeting Effects 0.000 description 2
• CJQGELDTIZDJNE-UHFFFAOYSA-N tert-butyl 4-[[[2-[4-(4-acetylpiperazin-1-yl)anilino]-5-carbamoylpyrimidin-4-yl]amino]methyl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1NC1=NC=C(C(N)=O)C(NCC2CCN(CC2)C(=O)OC(C)(C)C)=N1 CJQGELDTIZDJNE-UHFFFAOYSA-N 0.000 description 2
• CKXZPVPIDOJLLM-UHFFFAOYSA-N tert-butyl n-piperidin-4-ylcarbamate Chemical class CC(C)(C)OC(=O)NC1CCNCC1 CKXZPVPIDOJLLM-UHFFFAOYSA-N 0.000 description 2
• YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
• 231100001274 therapeutic index Toxicity 0.000 description 2
• 125000005309 thioalkoxy group Chemical group 0.000 description 2
• 125000003396 thiol group Chemical group [H]S* 0.000 description 2
• 206010043554 thrombocytopenia Diseases 0.000 description 2
• 230000002537 thrombolytic effect Effects 0.000 description 2
• UJLAWZDWDVHWOW-YPMHNXCESA-N tofacitinib Chemical compound C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 UJLAWZDWDVHWOW-YPMHNXCESA-N 0.000 description 2
• 229960001350 tofacitinib Drugs 0.000 description 2
• JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
• 230000001256 tonic effect Effects 0.000 description 2
• 230000000699 topical effect Effects 0.000 description 2
• 231100000331 toxic Toxicity 0.000 description 2
• 230000002588 toxic effect Effects 0.000 description 2
• GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
• 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
• RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
• LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
• 230000008026 type II hypersensitivity Effects 0.000 description 2
• 230000005951 type IV hypersensitivity Effects 0.000 description 2
• 230000036642 wellbeing Effects 0.000 description 2
• 239000000080 wetting agent Substances 0.000 description 2
• 239000003871 white petrolatum Substances 0.000 description 2
• LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
• VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 1
• RQEUFEKYXDPUSK-ZETCQYMHSA-N (1S)-1-phenylethanamine Chemical compound C[C@H](N)C1=CC=CC=C1 RQEUFEKYXDPUSK-ZETCQYMHSA-N 0.000 description 1
• DOMQFIFVDIAOOT-ROUUACIJSA-N (2S,3R)-N-[4-(2,6-dimethoxyphenyl)-5-(5-methylpyridin-3-yl)-1,2,4-triazol-3-yl]-3-(5-methylpyrimidin-2-yl)butane-2-sulfonamide Chemical compound COC1=C(C(=CC=C1)OC)N1C(=NN=C1C=1C=NC=C(C=1)C)NS(=O)(=O)[C@@H](C)[C@H](C)C1=NC=C(C=N1)C DOMQFIFVDIAOOT-ROUUACIJSA-N 0.000 description 1
• LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
• IXHNFOOSLAWRBQ-UHFFFAOYSA-N (3,4-dichlorophenyl)methanamine Chemical compound NCC1=CC=C(Cl)C(Cl)=C1 IXHNFOOSLAWRBQ-UHFFFAOYSA-N 0.000 description 1
• KTCOAUZKPQTUHT-UHFFFAOYSA-N (4-aminocyclohexyl)carbamic acid Chemical compound NC1CCC(NC(O)=O)CC1 KTCOAUZKPQTUHT-UHFFFAOYSA-N 0.000 description 1
• YQOLEILXOBUDMU-KRWDZBQOSA-N (4R)-5-[(6-bromo-3-methyl-2-pyrrolidin-1-ylquinoline-4-carbonyl)amino]-4-(2-chlorophenyl)pentanoic acid Chemical compound CC1=C(C2=C(C=CC(=C2)Br)N=C1N3CCCC3)C(=O)NC[C@H](CCC(=O)O)C4=CC=CC=C4Cl YQOLEILXOBUDMU-KRWDZBQOSA-N 0.000 description 1
• 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
• WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
• UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
• 229930182837 (R)-adrenaline Natural products 0.000 description 1
• UKGJZDSUJSPAJL-YPUOHESYSA-N (e)-n-[(1r)-1-[3,5-difluoro-4-(methanesulfonamido)phenyl]ethyl]-3-[2-propyl-6-(trifluoromethyl)pyridin-3-yl]prop-2-enamide Chemical compound CCCC1=NC(C(F)(F)F)=CC=C1\C=C\C(=O)N[C@H](C)C1=CC(F)=C(NS(C)(=O)=O)C(F)=C1 UKGJZDSUJSPAJL-YPUOHESYSA-N 0.000 description 1
• ZGYIXVSQHOKQRZ-COIATFDQSA-N (e)-n-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]-3-cyano-7-[(3s)-oxolan-3-yl]oxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide Chemical compound N#CC1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 ZGYIXVSQHOKQRZ-COIATFDQSA-N 0.000 description 1
• MOWXJLUYGFNTAL-DEOSSOPVSA-N (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxypyridazin-3-yl)methanol Chemical compound N1=NC(OC)=CC=C1[C@@H](O)C1=CC(C=2C3=CC=C(C=C3N=CN=2)N2CCOCC2)=C(F)C=C1Cl MOWXJLUYGFNTAL-DEOSSOPVSA-N 0.000 description 1
• ZJYIRVSPPOOPCL-UHFFFAOYSA-N 1,3-benzoxazol-6-amine Chemical compound NC1=CC=C2N=COC2=C1 ZJYIRVSPPOOPCL-UHFFFAOYSA-N 0.000 description 1
• FQUYSHZXSKYCSY-UHFFFAOYSA-N 1,4-diazepane Chemical compound C1CNCCNC1 FQUYSHZXSKYCSY-UHFFFAOYSA-N 0.000 description 1
• 125000000196 1,4-pentadienyl group Chemical group [H]C([*])=C([H])C([H])([H])C([H])=C([H])[H] 0.000 description 1
• WHSJJNSDVXKXFY-UHFFFAOYSA-N 1-(1-methoxyethyl)piperazine Chemical compound COC(C)N1CCNCC1 WHSJJNSDVXKXFY-UHFFFAOYSA-N 0.000 description 1
• APWRZPQBPCAXFP-UHFFFAOYSA-N 1-(1-oxo-2H-isoquinolin-5-yl)-5-(trifluoromethyl)-N-[2-(trifluoromethyl)pyridin-4-yl]pyrazole-4-carboxamide Chemical compound O=C1NC=CC2=C(C=CC=C12)N1N=CC(=C1C(F)(F)F)C(=O)NC1=CC(=NC=C1)C(F)(F)F APWRZPQBPCAXFP-UHFFFAOYSA-N 0.000 description 1
• VWOJSRICSKDKAW-UHFFFAOYSA-N 1-(4-nitrophenyl)piperazine Chemical compound C1=CC([N+](=O)[O-])=CC=C1N1CCNCC1 VWOJSRICSKDKAW-UHFFFAOYSA-N 0.000 description 1
• DNUTZBZXLPWRJG-UHFFFAOYSA-N 1-Piperidine carboxylic acid Chemical compound OC(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-N 0.000 description 1
• KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 1
• ABDDQTDRAHXHOC-QMMMGPOBSA-N 1-[(7s)-5,7-dihydro-4h-thieno[2,3-c]pyran-7-yl]-n-methylmethanamine Chemical compound CNC[C@@H]1OCCC2=C1SC=C2 ABDDQTDRAHXHOC-QMMMGPOBSA-N 0.000 description 1
• CGLNAGNYUPXMKH-UHFFFAOYSA-N 1-[4-(5-aminopyridin-2-yl)piperazin-1-yl]ethanone Chemical compound C1CN(C(=O)C)CCN1C1=CC=C(N)C=N1 CGLNAGNYUPXMKH-UHFFFAOYSA-N 0.000 description 1
• ZKYDQWRFCPGRNU-UHFFFAOYSA-N 1-[4-[4-[[4-(cyclopropylamino)pyrimidin-2-yl]amino]benzoyl]piperazin-1-yl]ethanone Chemical compound C(C)(=O)N1CCN(CC1)C(=O)C1=CC=C(C=C1)NC1=NC=CC(=N1)NC1CC1 ZKYDQWRFCPGRNU-UHFFFAOYSA-N 0.000 description 1
• JKRJYAKPRGBXGS-UHFFFAOYSA-N 1-[4-[[5-carbamoyl-4-(cyclopropylamino)pyrimidin-2-yl]amino]phenyl]piperidine-4-carboxylic acid Chemical compound N1=C(NC2CC2)C(C(=O)N)=CN=C1NC(C=C1)=CC=C1N1CCC(C(O)=O)CC1 JKRJYAKPRGBXGS-UHFFFAOYSA-N 0.000 description 1
• VFWCMGCRMGJXDK-UHFFFAOYSA-N 1-chlorobutane Chemical class CCCCCl VFWCMGCRMGJXDK-UHFFFAOYSA-N 0.000 description 1
• VUQPJRPDRDVQMN-UHFFFAOYSA-N 1-chlorooctadecane Chemical class CCCCCCCCCCCCCCCCCCCl VUQPJRPDRDVQMN-UHFFFAOYSA-N 0.000 description 1
• KDKGWGUUUVROTO-UHFFFAOYSA-N 1-hydroxypiperazine Chemical compound ON1CCNCC1 KDKGWGUUUVROTO-UHFFFAOYSA-N 0.000 description 1
• SCCCFNJTCDSLCY-UHFFFAOYSA-N 1-iodo-4-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(I)C=C1 SCCCFNJTCDSLCY-UHFFFAOYSA-N 0.000 description 1
• ODOJPFQQFJVNMD-UHFFFAOYSA-N 1-methylindol-4-amine Chemical compound C1=CC=C2N(C)C=CC2=C1N ODOJPFQQFJVNMD-UHFFFAOYSA-N 0.000 description 1
• 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
• IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
• RQEUFEKYXDPUSK-UHFFFAOYSA-N 1-phenylethylamine Chemical compound CC(N)C1=CC=CC=C1 RQEUFEKYXDPUSK-UHFFFAOYSA-N 0.000 description 1
• HTGCVLNFLVVCST-UHFFFAOYSA-N 1-piperazin-1-ylethanol Chemical class CC(O)N1CCNCC1 HTGCVLNFLVVCST-UHFFFAOYSA-N 0.000 description 1
• 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
• 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 description 1
• BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
• KJUGUADJHNHALS-UHFFFAOYSA-N 1H-tetrazole Substances C=1N=NNN=1 KJUGUADJHNHALS-UHFFFAOYSA-N 0.000 description 1
• XBTOSRUBOXQWBO-UHFFFAOYSA-N 1h-indazol-5-amine Chemical compound NC1=CC=C2NN=CC2=C1 XBTOSRUBOXQWBO-UHFFFAOYSA-N 0.000 description 1
• 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
• CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
• BTTNYQZNBZNDOR-UHFFFAOYSA-N 2,4-dichloropyrimidine Chemical compound ClC1=CC=NC(Cl)=N1 BTTNYQZNBZNDOR-UHFFFAOYSA-N 0.000 description 1
• WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical class OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 1
• QZQFFKMCNCNZFZ-UHFFFAOYSA-N 2-(1,2-dihydrobenzo[d][1]benzoxepin-1-yl)-4,5-dihydro-3h-1,2-benzoxazepine Chemical compound C1CCC2=CC=CC=C2ON1C1C(C=2C(=CC=CC=2)C=CO2)=C2C=CC1 QZQFFKMCNCNZFZ-UHFFFAOYSA-N 0.000 description 1
• PPTJZCLHYPQDSJ-UHFFFAOYSA-N 2-(4-aminophenyl)-2-methylpropanamide Chemical compound NC(=O)C(C)(C)C1=CC=C(N)C=C1 PPTJZCLHYPQDSJ-UHFFFAOYSA-N 0.000 description 1
• YVUJUJYBPUQLQU-UHFFFAOYSA-N 2-(4-aminophenyl)propanamide Chemical compound NC(=O)C(C)C1=CC=C(N)C=C1 YVUJUJYBPUQLQU-UHFFFAOYSA-N 0.000 description 1
• GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 description 1
• HUHXLHLWASNVDB-UHFFFAOYSA-N 2-(oxan-2-yloxy)oxane Chemical class O1CCCCC1OC1OCCCC1 HUHXLHLWASNVDB-UHFFFAOYSA-N 0.000 description 1
• NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
• FJUKIPMCEFHCDC-UHFFFAOYSA-N 2-[4-(4-acetylpiperazin-1-yl)anilino]-4-(3-methoxyanilino)pyrimidine-5-carboxamide Chemical compound COC1=CC=CC(NC=2C(=CN=C(NC=3C=CC(=CC=3)N3CCN(CC3)C(C)=O)N=2)C(N)=O)=C1 FJUKIPMCEFHCDC-UHFFFAOYSA-N 0.000 description 1
• ODOCPUAAXZORNM-UHFFFAOYSA-N 2-[4-(4-acetylpiperazin-1-yl)anilino]-4-(cyanomethylamino)pyrimidine-5-carboxamide Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1NC1=NC=C(C(N)=O)C(NCC#N)=N1 ODOCPUAAXZORNM-UHFFFAOYSA-N 0.000 description 1
• YMYMCGLMYUMRBN-UHFFFAOYSA-N 2-[4-(4-acetylpiperazin-1-yl)anilino]-4-(cyclopropylamino)pyrimidine-5-carboxamide Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1NC1=NC=C(C(N)=O)C(NC2CC2)=N1 YMYMCGLMYUMRBN-UHFFFAOYSA-N 0.000 description 1
• HHQGTMZTKZVVHN-UHFFFAOYSA-N 2-[4-(4-acetylpiperazin-1-yl)anilino]-4-(tert-butylamino)pyrimidine-5-carboxamide Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1NC1=NC=C(C(N)=O)C(NC(C)(C)C)=N1 HHQGTMZTKZVVHN-UHFFFAOYSA-N 0.000 description 1
• NXFKIKCJNBVJNC-UHFFFAOYSA-N 2-[4-(4-acetylpiperazin-1-yl)anilino]-4-[(1-carbamoylpiperidin-4-yl)methylamino]pyrimidine-5-carboxamide Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1NC1=NC=C(C(N)=O)C(NCC2CCN(CC2)C(N)=O)=N1 NXFKIKCJNBVJNC-UHFFFAOYSA-N 0.000 description 1
• SYAIHPHAYGOQIX-UHFFFAOYSA-N 2-[4-(4-acetylpiperazin-1-yl)anilino]-4-[(1-methylsulfonylpiperidin-4-yl)methylamino]pyrimidine-5-carboxamide Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1NC1=NC=C(C(N)=O)C(NCC2CCN(CC2)S(C)(=O)=O)=N1 SYAIHPHAYGOQIX-UHFFFAOYSA-N 0.000 description 1
• AIXZFNJDQBLOAN-UHFFFAOYSA-N 2-[4-(4-acetylpiperazin-1-yl)anilino]-4-[(4-amino-4-oxobutyl)amino]pyrimidine-5-carboxamide Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1NC1=NC=C(C(N)=O)C(NCCCC(N)=O)=N1 AIXZFNJDQBLOAN-UHFFFAOYSA-N 0.000 description 1
• JTXMVXSTHSMVQF-UHFFFAOYSA-N 2-acetyloxyethyl acetate Chemical compound CC(=O)OCCOC(C)=O JTXMVXSTHSMVQF-UHFFFAOYSA-N 0.000 description 1
• MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
• 125000004174 2-benzimidazolyl group Chemical group [H]N1C(*)=NC2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
• GRWKNBPOGBTZMN-UHFFFAOYSA-N 2-benzyl-3-phenylpropane-1,2-diamine Chemical compound C=1C=CC=CC=1CC(N)(CN)CC1=CC=CC=C1 GRWKNBPOGBTZMN-UHFFFAOYSA-N 0.000 description 1
• BAZVFQBTJPBRTJ-UHFFFAOYSA-N 2-chloro-5-nitropyridine Chemical compound [O-][N+](=O)C1=CC=C(Cl)N=C1 BAZVFQBTJPBRTJ-UHFFFAOYSA-N 0.000 description 1
• 125000001731 2-cyanoethyl group Chemical group [H]C([H])(*)C([H])([H])C#N 0.000 description 1
• BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
• 229940013085 2-diethylaminoethanol Drugs 0.000 description 1
• 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
• 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
• JJKWHOSQTYYFAE-UHFFFAOYSA-N 2-methoxyacetyl chloride Chemical compound COCC(Cl)=O JJKWHOSQTYYFAE-UHFFFAOYSA-N 0.000 description 1
• 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
• 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
• 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
• LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
• WMPPDTMATNBGJN-UHFFFAOYSA-N 2-phenylethylbromide Chemical class BrCCC1=CC=CC=C1 WMPPDTMATNBGJN-UHFFFAOYSA-N 0.000 description 1
• 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
• 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
• 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 1
• 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
• LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
• FPENCTDAQQQKNY-UHFFFAOYSA-N 3,4-difluorobenzoic acid Chemical compound OC(=O)C1=CC=C(F)C(F)=C1 FPENCTDAQQQKNY-UHFFFAOYSA-N 0.000 description 1
• PLYTVAFAKDFFKM-UHFFFAOYSA-N 3,4-dimethylmorpholine Chemical compound CC1COCCN1C PLYTVAFAKDFFKM-UHFFFAOYSA-N 0.000 description 1
• HCDMJFOHIXMBOV-UHFFFAOYSA-N 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one Chemical compound C=1C2=C3N(CC)C(=O)N(C=4C(=C(OC)C=C(OC)C=4F)F)CC3=CN=C2NC=1CN1CCOCC1 HCDMJFOHIXMBOV-UHFFFAOYSA-N 0.000 description 1
• BYHQTRFJOGIQAO-GOSISDBHSA-N 3-(4-bromophenyl)-8-[(2R)-2-hydroxypropyl]-1-[(3-methoxyphenyl)methyl]-1,3,8-triazaspiro[4.5]decan-2-one Chemical compound C[C@H](CN1CCC2(CC1)CN(C(=O)N2CC3=CC(=CC=C3)OC)C4=CC=C(C=C4)Br)O BYHQTRFJOGIQAO-GOSISDBHSA-N 0.000 description 1
• YGYGASJNJTYNOL-CQSZACIVSA-N 3-[(4r)-2,2-dimethyl-1,1-dioxothian-4-yl]-5-(4-fluorophenyl)-1h-indole-7-carboxamide Chemical compound C1CS(=O)(=O)C(C)(C)C[C@@H]1C1=CNC2=C(C(N)=O)C=C(C=3C=CC(F)=CC=3)C=C12 YGYGASJNJTYNOL-CQSZACIVSA-N 0.000 description 1
• WNEODWDFDXWOLU-QHCPKHFHSA-N 3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2s)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl]amino]-6-oxopyridin-3-yl]pyridin-2-yl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one Chemical compound C([C@@H](N(CC1)C=2C=NC(NC=3C(N(C)C=C(C=3)C=3C(=C(N4C(C5=CC=6CC(C)(C)CC=6N5CC4)=O)N=CC=3)CO)=O)=CC=2)C)N1C1COC1 WNEODWDFDXWOLU-QHCPKHFHSA-N 0.000 description 1
• 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
• XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 description 1
• 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
• 125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 description 1
• 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
• WEQPBCSPRXFQQS-UHFFFAOYSA-N 4,5-dihydro-1,2-oxazole Chemical compound C1CC=NO1 WEQPBCSPRXFQQS-UHFFFAOYSA-N 0.000 description 1
• OTYZNDKWNPQQJP-UHFFFAOYSA-N 4-(2-pyrrolidin-1-ylethoxy)aniline Chemical compound C1=CC(N)=CC=C1OCCN1CCCC1 OTYZNDKWNPQQJP-UHFFFAOYSA-N 0.000 description 1
• OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
• QTYRAOOHLZVFGP-UHFFFAOYSA-N 4-(4-nitrophenyl)piperazine-1-carboxamide Chemical compound C1CN(C(=O)N)CCN1C1=CC=C([N+]([O-])=O)C=C1 QTYRAOOHLZVFGP-UHFFFAOYSA-N 0.000 description 1
• LPBGPDKSWUGPBT-UHFFFAOYSA-N 4-(cyclopropylamino)-2-(quinolin-6-ylamino)pyrimidine-5-carboxamide Chemical compound NC(=O)C1=CN=C(NC=2C=C3C=CC=NC3=CC=2)N=C1NC1CC1 LPBGPDKSWUGPBT-UHFFFAOYSA-N 0.000 description 1
• RGOZWVYEQRUTTA-UHFFFAOYSA-N 4-(cyclopropylamino)-2-[4-(3,3-difluoropyrrolidin-1-yl)anilino]pyrimidine-5-carboxamide Chemical compound N1=C(NC2CC2)C(C(=O)N)=CN=C1NC(C=C1)=CC=C1N1CCC(F)(F)C1 RGOZWVYEQRUTTA-UHFFFAOYSA-N 0.000 description 1
• DPBWFNDFMCCGGJ-UHFFFAOYSA-N 4-Piperidine carboxamide Chemical compound NC(=O)C1CCNCC1 DPBWFNDFMCCGGJ-UHFFFAOYSA-N 0.000 description 1
• VJPPLCNBDLZIFG-ZDUSSCGKSA-N 4-[(3S)-3-(but-2-ynoylamino)piperidin-1-yl]-5-fluoro-2,3-dimethyl-1H-indole-7-carboxamide Chemical compound C(C#CC)(=O)N[C@@H]1CN(CCC1)C1=C2C(=C(NC2=C(C=C1F)C(=O)N)C)C VJPPLCNBDLZIFG-ZDUSSCGKSA-N 0.000 description 1
• YFCIFWOJYYFDQP-PTWZRHHISA-N 4-[3-amino-6-[(1S,3S,4S)-3-fluoro-4-hydroxycyclohexyl]pyrazin-2-yl]-N-[(1S)-1-(3-bromo-5-fluorophenyl)-2-(methylamino)ethyl]-2-fluorobenzamide Chemical compound CNC[C@@H](NC(=O)c1ccc(cc1F)-c1nc(cnc1N)[C@H]1CC[C@H](O)[C@@H](F)C1)c1cc(F)cc(Br)c1 YFCIFWOJYYFDQP-PTWZRHHISA-N 0.000 description 1
• XYWIPYBIIRTJMM-IBGZPJMESA-N 4-[[(2S)-2-[4-[5-chloro-2-[4-(trifluoromethyl)triazol-1-yl]phenyl]-5-methoxy-2-oxopyridin-1-yl]butanoyl]amino]-2-fluorobenzamide Chemical compound CC[C@H](N1C=C(OC)C(=CC1=O)C1=C(C=CC(Cl)=C1)N1C=C(N=N1)C(F)(F)F)C(=O)NC1=CC(F)=C(C=C1)C(N)=O XYWIPYBIIRTJMM-IBGZPJMESA-N 0.000 description 1
• KVCQTKNUUQOELD-UHFFFAOYSA-N 4-amino-n-[1-(3-chloro-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=CC(Cl)=C1F KVCQTKNUUQOELD-UHFFFAOYSA-N 0.000 description 1
• IMLXLGZJLAOKJN-UHFFFAOYSA-N 4-aminocyclohexan-1-ol Chemical compound NC1CCC(O)CC1 IMLXLGZJLAOKJN-UHFFFAOYSA-N 0.000 description 1
• JHFOWEGCZWLHNW-UHFFFAOYSA-N 4-fluoro-2-methyl-1-nitrobenzene Chemical class CC1=CC(F)=CC=C1[N+]([O-])=O JHFOWEGCZWLHNW-UHFFFAOYSA-N 0.000 description 1
• HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
• VLVCDUSVTXIWGW-UHFFFAOYSA-N 4-iodoaniline Chemical class NC1=CC=C(I)C=C1 VLVCDUSVTXIWGW-UHFFFAOYSA-N 0.000 description 1
• MVQZLTGVYORDOO-UHFFFAOYSA-N 4-n-(3-methoxyphenyl)-2-n-[4-(2-pyrrolidin-1-ylethoxy)phenyl]pyrimidine-2,4-diamine Chemical compound COC1=CC=CC(NC=2N=C(NC=3C=CC(OCCN4CCCC4)=CC=3)N=CC=2)=C1 MVQZLTGVYORDOO-UHFFFAOYSA-N 0.000 description 1
• 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
• KDDQRKBRJSGMQE-UHFFFAOYSA-N 4-thiazolyl Chemical group [C]1=CSC=N1 KDDQRKBRJSGMQE-UHFFFAOYSA-N 0.000 description 1
• IRPVABHDSJVBNZ-RTHVDDQRSA-N 5-[1-(cyclopropylmethyl)-5-[(1R,5S)-3-(oxetan-3-yl)-3-azabicyclo[3.1.0]hexan-6-yl]pyrazol-3-yl]-3-(trifluoromethyl)pyridin-2-amine Chemical compound C1=C(C(F)(F)F)C(N)=NC=C1C1=NN(CC2CC2)C(C2[C@@H]3CN(C[C@@H]32)C2COC2)=C1 IRPVABHDSJVBNZ-RTHVDDQRSA-N 0.000 description 1
• LQGKDMHENBFVRC-UHFFFAOYSA-N 5-aminopentan-1-ol Chemical compound NCCCCCO LQGKDMHENBFVRC-UHFFFAOYSA-N 0.000 description 1
• CWDWFSXUQODZGW-UHFFFAOYSA-N 5-thiazolyl Chemical group [C]1=CN=CS1 CWDWFSXUQODZGW-UHFFFAOYSA-N 0.000 description 1
• KCBWAFJCKVKYHO-UHFFFAOYSA-N 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-[[4-[1-propan-2-yl-4-(trifluoromethyl)imidazol-2-yl]phenyl]methyl]pyrazolo[3,4-d]pyrimidine Chemical compound C1(CC1)C1=NC=NC(=C1C1=NC=C2C(=N1)N(N=C2)CC1=CC=C(C=C1)C=1N(C=C(N=1)C(F)(F)F)C(C)C)OC KCBWAFJCKVKYHO-UHFFFAOYSA-N 0.000 description 1
• NFWVCYWFUIFIKU-UHFFFAOYSA-N 6-amino-3,4-dihydro-1h-quinolin-2-one Chemical compound N1C(=O)CCC2=CC(N)=CC=C21 NFWVCYWFUIFIKU-UHFFFAOYSA-N 0.000 description 1
• FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
• CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 1
• QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
• ZRPZPNYZFSJUPA-UHFFFAOYSA-N ARS-1620 Chemical compound Oc1cccc(F)c1-c1c(Cl)cc2c(ncnc2c1F)N1CCN(CC1)C(=O)C=C ZRPZPNYZFSJUPA-UHFFFAOYSA-N 0.000 description 1
• 108010044267 Abnormal Hemoglobins Proteins 0.000 description 1
• 206010000871 Acute monocytic leukaemia Diseases 0.000 description 1
• 206010000890 Acute myelomonocytic leukaemia Diseases 0.000 description 1
• 208000016585 Acute panmyelosis with myelofibrosis Diseases 0.000 description 1
• 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 1
• 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
• 201000004384 Alopecia Diseases 0.000 description 1
• 208000024827 Alzheimer disease Diseases 0.000 description 1
• USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
• 239000005695 Ammonium acetate Substances 0.000 description 1
• 244000144725 Amygdalus communis Species 0.000 description 1
• 235000011437 Amygdalus communis Nutrition 0.000 description 1
• 206010002198 Anaphylactic reaction Diseases 0.000 description 1
• 206010002329 Aneurysm Diseases 0.000 description 1
• 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
• 102000006306 Antigen Receptors Human genes 0.000 description 1
• 108010083359 Antigen Receptors Proteins 0.000 description 1
• 101000719121 Arabidopsis thaliana Protein MEI2-like 1 Proteins 0.000 description 1
• 206010003178 Arterial thrombosis Diseases 0.000 description 1
• 208000000104 Arthus reaction Diseases 0.000 description 1
• BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
• 241000416162 Astragalus gummifer Species 0.000 description 1
• 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
• 102000019260 B-Cell Antigen Receptors Human genes 0.000 description 1
• 108010012919 B-Cell Antigen Receptors Proteins 0.000 description 1
• 208000025324 B-cell acute lymphoblastic leukemia Diseases 0.000 description 1
• 208000025321 B-lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
• 239000004342 Benzoyl peroxide Substances 0.000 description 1
• OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
• BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
• LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
• 206010005003 Bladder cancer Diseases 0.000 description 1
• 208000020084 Bone disease Diseases 0.000 description 1
• WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
• COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
• FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
• FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
• 125000004648 C2-C8 alkenyl group Chemical group 0.000 description 1
• 125000004649 C2-C8 alkynyl group Chemical group 0.000 description 1
• PZVPWWCMQCITPG-UHFFFAOYSA-N CC(=O)N1CCN(C(=O)C1)C2=CC=C(C=C2)NC3=NC=CC(=N3)NC4CC4 Chemical compound CC(=O)N1CCN(C(=O)C1)C2=CC=C(C=C2)NC3=NC=CC(=N3)NC4CC4 PZVPWWCMQCITPG-UHFFFAOYSA-N 0.000 description 1
• QTCPSNYZEZNKPN-UHFFFAOYSA-N CC(=O)N1CCN(CC1)C2=C(C=C(C=C2)NC3=NC=CC(=N3)NC4CC4)Cl Chemical compound CC(=O)N1CCN(CC1)C2=C(C=C(C=C2)NC3=NC=CC(=N3)NC4CC4)Cl QTCPSNYZEZNKPN-UHFFFAOYSA-N 0.000 description 1
• VLPOKADBYHTMQZ-UHFFFAOYSA-N CC(=O)N1CCN(CC1)C2=C(C=C(C=C2)NC3=NC=CC(=N3)NC4CC4)F Chemical compound CC(=O)N1CCN(CC1)C2=C(C=C(C=C2)NC3=NC=CC(=N3)NC4CC4)F VLPOKADBYHTMQZ-UHFFFAOYSA-N 0.000 description 1
• DAOYLIFLFGSPGB-UHFFFAOYSA-N CC(=O)N1CCN(CC1)C2=NC=C(C=C2)NC3=NC=CC(=N3)NC4CC4 Chemical compound CC(=O)N1CCN(CC1)C2=NC=C(C=C2)NC3=NC=CC(=N3)NC4CC4 DAOYLIFLFGSPGB-UHFFFAOYSA-N 0.000 description 1
• 102100031077 Calcineurin B homologous protein 3 Human genes 0.000 description 1
• OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
• BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
• 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
• VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
• KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
• ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
• 206010008805 Chromosomal abnormalities Diseases 0.000 description 1
• 101150065749 Churc1 gene Proteins 0.000 description 1
• KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
• 208000010007 Cogan syndrome Diseases 0.000 description 1
• 108010048623 Collagen Receptors Proteins 0.000 description 1
• 102000009268 Collagen Receptors Human genes 0.000 description 1
• RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
• 208000011231 Crohn disease Diseases 0.000 description 1
• 102100039683 Cyclin-G-associated kinase Human genes 0.000 description 1
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
• 108700020911 DNA-Binding Proteins Proteins 0.000 description 1
• 102000052510 DNA-Binding Proteins Human genes 0.000 description 1
• 101710088194 Dehydrogenase Proteins 0.000 description 1
• 206010012442 Dermatitis contact Diseases 0.000 description 1
• 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
• XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical class C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
• SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
• LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
• 241000402754 Erythranthe moschata Species 0.000 description 1
• 208000036566 Erythroleukaemia Diseases 0.000 description 1
• 239000001856 Ethyl cellulose Substances 0.000 description 1
• ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
• PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
• 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
• 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
• GISRWBROCYNDME-PELMWDNLSA-N F[C@H]1[C@H]([C@H](NC1=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N)C Chemical compound F[C@H]1[C@H]([C@H](NC1=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N)C GISRWBROCYNDME-PELMWDNLSA-N 0.000 description 1
• 240000000731 Fagus sylvatica Species 0.000 description 1
• 235000010099 Fagus sylvatica Nutrition 0.000 description 1
• 108010049003 Fibrinogen Proteins 0.000 description 1
• 102000008946 Fibrinogen Human genes 0.000 description 1
• 206010018364 Glomerulonephritis Diseases 0.000 description 1
• 239000004471 Glycine Substances 0.000 description 1
• 208000024869 Goodpasture syndrome Diseases 0.000 description 1
• 208000009329 Graft vs Host Disease Diseases 0.000 description 1
• 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
• 101001094700 Homo sapiens POU domain, class 5, transcription factor 1 Proteins 0.000 description 1
• 101000857677 Homo sapiens Runt-related transcription factor 1 Proteins 0.000 description 1
• 101000713275 Homo sapiens Solute carrier family 22 member 3 Proteins 0.000 description 1
• 108091006905 Human Serum Albumin Proteins 0.000 description 1
• 102000008100 Human Serum Albumin Human genes 0.000 description 1
• AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
• GRSZFWQUAKGDAV-KQYNXXCUSA-N IMP Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC=NC2=O)=C2N=C1 GRSZFWQUAKGDAV-KQYNXXCUSA-N 0.000 description 1
• 108010058683 Immobilized Proteins Proteins 0.000 description 1
• 206010062016 Immunosuppression Diseases 0.000 description 1
• 206010061216 Infarction Diseases 0.000 description 1
• 108010017642 Integrin alpha2beta1 Proteins 0.000 description 1
• 102000018682 Interleukin Receptor Common gamma Subunit Human genes 0.000 description 1
• 108010066719 Interleukin Receptor Common gamma Subunit Proteins 0.000 description 1
• 102000004388 Interleukin-4 Human genes 0.000 description 1
• 108090000978 Interleukin-4 Proteins 0.000 description 1
• LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
• 206010023126 Jaundice Diseases 0.000 description 1
• 101150092727 KLF10 gene Proteins 0.000 description 1
• 208000002260 Keloid Diseases 0.000 description 1
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
• HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
• JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
• 241000761557 Lamina Species 0.000 description 1
• 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 1
• WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
• 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
• 206010025327 Lymphopenia Diseases 0.000 description 1
• WAEMQWOKJMHJLA-UHFFFAOYSA-N Manganese(2+) Chemical compound [Mn+2] WAEMQWOKJMHJLA-UHFFFAOYSA-N 0.000 description 1
• 206010027476 Metastases Diseases 0.000 description 1
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
• 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
• 208000019695 Migraine disease Diseases 0.000 description 1
• 208000035489 Monocytic Acute Leukemia Diseases 0.000 description 1
• 101100448410 Mus musculus Gkn1 gene Proteins 0.000 description 1
• 208000033835 Myelomonocytic Acute Leukemia Diseases 0.000 description 1
• 208000033833 Myelomonocytic Chronic Leukemia Diseases 0.000 description 1
• 208000037538 Myelomonocytic Juvenile Leukemia Diseases 0.000 description 1
• 201000007224 Myeloproliferative neoplasm Diseases 0.000 description 1
• SIYVXIIUIKCKLS-UHFFFAOYSA-N N'-[4-(4-acetylpiperazin-1-yl)phenyl]pyrimidine-5-carbohydrazide Chemical compound N1=CN=CC(=C1)C(=O)NNC1=CC=C(C=C1)N1CCN(CC1)C(C)=O SIYVXIIUIKCKLS-UHFFFAOYSA-N 0.000 description 1
• AYCPARAPKDAOEN-LJQANCHMSA-N N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methyl-4-thieno[3,2-d]pyrimidinyl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide Chemical compound C1([C@H](NC(=O)N2C(C=3NN=C(NC=4C=5SC=CC=5N=C(C)N=4)C=3C2)(C)C)CN(C)C)=CC=CC=C1 AYCPARAPKDAOEN-LJQANCHMSA-N 0.000 description 1
• FEYNFHSRETUBEM-UHFFFAOYSA-N N-[3-(1,1-difluoroethyl)phenyl]-1-(4-methoxyphenyl)-3-methyl-5-oxo-4H-pyrazole-4-carboxamide Chemical compound COc1ccc(cc1)N1N=C(C)C(C(=O)Nc2cccc(c2)C(C)(F)F)C1=O FEYNFHSRETUBEM-UHFFFAOYSA-N 0.000 description 1
• UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
• MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
• 206010028851 Necrosis Diseases 0.000 description 1
• 208000012902 Nervous system disease Diseases 0.000 description 1
• 208000025966 Neurological disease Diseases 0.000 description 1
• 208000033755 Neutrophilic Chronic Leukemia Diseases 0.000 description 1
• PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
• 108091028043 Nucleic acid sequence Proteins 0.000 description 1
• IDRGFNPZDVBSSE-UHFFFAOYSA-N OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F Chemical compound OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F IDRGFNPZDVBSSE-UHFFFAOYSA-N 0.000 description 1
• 239000005642 Oleic acid Substances 0.000 description 1
• ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
• 108091034117 Oligonucleotide Proteins 0.000 description 1
• 206010033128 Ovarian cancer Diseases 0.000 description 1
• 206010061535 Ovarian neoplasm Diseases 0.000 description 1
• MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
• 108010035766 P-Selectin Proteins 0.000 description 1
• 102100023472 P-selectin Human genes 0.000 description 1
• 239000012826 P38 inhibitor Substances 0.000 description 1
• 102100035423 POU domain, class 5, transcription factor 1 Human genes 0.000 description 1
• 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
• 206010033661 Pancytopenia Diseases 0.000 description 1
• 208000037273 Pathologic Processes Diseases 0.000 description 1
• 235000019483 Peanut oil Nutrition 0.000 description 1
• 206010034277 Pemphigoid Diseases 0.000 description 1
• 241000721454 Pemphigus Species 0.000 description 1
• 208000027190 Peripheral T-cell lymphomas Diseases 0.000 description 1
• 108010089430 Phosphoproteins Proteins 0.000 description 1
• 102000007982 Phosphoproteins Human genes 0.000 description 1
• 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
• 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical class OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
• 206010035226 Plasma cell myeloma Diseases 0.000 description 1
• 208000007452 Plasmacytoma Diseases 0.000 description 1
• 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
• 239000004698 Polyethylene Substances 0.000 description 1
• 229920001214 Polysorbate 60 Polymers 0.000 description 1
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
• 102100034368 Potassium voltage-gated channel subfamily A member 1 Human genes 0.000 description 1
• 101710154114 Potassium voltage-gated channel subfamily A member 1 Proteins 0.000 description 1
• 206010065857 Primary Effusion Lymphoma Diseases 0.000 description 1
• 241000288906 Primates Species 0.000 description 1
• 208000033759 Prolymphocytic T-Cell Leukemia Diseases 0.000 description 1
• 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 description 1
• WUGQZFFCHPXWKQ-UHFFFAOYSA-N Propanolamine Chemical compound NCCCO WUGQZFFCHPXWKQ-UHFFFAOYSA-N 0.000 description 1
• XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
• 102000007327 Protamines Human genes 0.000 description 1
• 108010007568 Protamines Proteins 0.000 description 1
• 102100038239 Protein Churchill Human genes 0.000 description 1
• 102000002727 Protein Tyrosine Phosphatase Human genes 0.000 description 1
• 206010037549 Purpura Diseases 0.000 description 1
• 241001672981 Purpura Species 0.000 description 1
• 239000007868 Raney catalyst Substances 0.000 description 1
• NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
• 229910000564 Raney nickel Inorganic materials 0.000 description 1
• 108700008625 Reporter Genes Proteins 0.000 description 1
• 206010039085 Rhinitis allergic Diseases 0.000 description 1
• 102100025373 Runt-related transcription factor 1 Human genes 0.000 description 1
• 125000000066 S-methyl group Chemical group [H]C([H])([H])S* 0.000 description 1
• 101100178269 Schizosaccharomyces pombe (strain 972 / ATCC 24843) hob1 gene Proteins 0.000 description 1
• 206010039710 Scleroderma Diseases 0.000 description 1
• 208000034189 Sclerosis Diseases 0.000 description 1
• 229940124639 Selective inhibitor Drugs 0.000 description 1
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
• 240000003801 Sigesbeckia orientalis Species 0.000 description 1
• 235000003407 Sigesbeckia orientalis Nutrition 0.000 description 1
• XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
• 108020004459 Small interfering RNA Proteins 0.000 description 1
• KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical class OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
• 230000024932 T cell mediated immunity Effects 0.000 description 1
• 208000031672 T-Cell Peripheral Lymphoma Diseases 0.000 description 1
• 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 description 1
• 201000011648 T-cell childhood lymphoblastic lymphoma Diseases 0.000 description 1
• 208000026651 T-cell prolymphocytic leukemia Diseases 0.000 description 1
• 208000020982 T-lymphoblastic lymphoma Diseases 0.000 description 1
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
• 239000004473 Threonine Substances 0.000 description 1
• 206010043561 Thrombocytopenic purpura Diseases 0.000 description 1
• 239000004012 Tofacitinib Substances 0.000 description 1
• 229920001615 Tragacanth Polymers 0.000 description 1
• 108091023040 Transcription factor Proteins 0.000 description 1
• 102000040945 Transcription factor Human genes 0.000 description 1
• YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
• 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
• 241000282458 Ursus sp. Species 0.000 description 1
• 206010047163 Vasospasm Diseases 0.000 description 1
• 241000700605 Viruses Species 0.000 description 1
• 108010046377 Whey Proteins Proteins 0.000 description 1
• HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
• LXRZVMYMQHNYJB-UNXOBOICSA-N [(1R,2S,4R)-4-[[5-[4-[(1R)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl]-5-methylthiophene-2-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate Chemical compound CC1=C(C=C(S1)C(=O)C1=C(N[C@H]2C[C@H](O)[C@@H](COS(N)(=O)=O)C2)N=CN=C1)[C@@H]1NCCC2=C1C=C(Cl)C=C2 LXRZVMYMQHNYJB-UNXOBOICSA-N 0.000 description 1
• PNDPGZBMCMUPRI-XXSWNUTMSA-N [125I][125I] Chemical compound [125I][125I] PNDPGZBMCMUPRI-XXSWNUTMSA-N 0.000 description 1
• 229940124532 absorption promoter Drugs 0.000 description 1
• 238000010521 absorption reaction Methods 0.000 description 1
• DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
• WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
• 239000012346 acetyl chloride Substances 0.000 description 1
• 229960001138 acetylsalicylic acid Drugs 0.000 description 1
• 239000013543 active substance Substances 0.000 description 1
• 208000021841 acute erythroid leukemia Diseases 0.000 description 1
• 208000011912 acute myelomonocytic leukemia M4 Diseases 0.000 description 1
• 230000010933 acylation Effects 0.000 description 1
• 238000005917 acylation reaction Methods 0.000 description 1
• 239000000853 adhesive Substances 0.000 description 1
• 230000001070 adhesive effect Effects 0.000 description 1
• WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
• 239000000443 aerosol Substances 0.000 description 1
• MJBWDEQAUQTVKK-IAGOWNOFSA-N aflatoxin M1 Chemical compound C=1([C@]2(O)C=CO[C@@H]2OC=1C=C(C1=2)OC)C=2OC(=O)C2=C1CCC2=O MJBWDEQAUQTVKK-IAGOWNOFSA-N 0.000 description 1
• 150000001298 alcohols Chemical class 0.000 description 1
• 229940072056 alginate Drugs 0.000 description 1
• 239000003513 alkali Substances 0.000 description 1
• 229910052783 alkali metal Inorganic materials 0.000 description 1
• 150000001342 alkaline earth metals Chemical class 0.000 description 1
• 125000004466 alkoxycarbonylamino group Chemical group 0.000 description 1
• 150000003973 alkyl amines Chemical class 0.000 description 1
• 125000004947 alkyl aryl amino group Chemical group 0.000 description 1
• 125000004448 alkyl carbonyl group Chemical group 0.000 description 1
• 125000005196 alkyl carbonyloxy group Chemical group 0.000 description 1
• 150000005215 alkyl ethers Chemical class 0.000 description 1
• 150000001350 alkyl halides Chemical class 0.000 description 1
• 125000004656 alkyl sulfonylamino group Chemical group 0.000 description 1
• 239000002168 alkylating agent Substances 0.000 description 1
• 229940100198 alkylating agent Drugs 0.000 description 1
• 125000005237 alkyleneamino group Chemical group 0.000 description 1
• 125000005275 alkylenearyl group Chemical group 0.000 description 1
• 125000005238 alkylenediamino group Chemical group 0.000 description 1
• 125000005530 alkylenedioxy group Chemical group 0.000 description 1
• 125000005529 alkyleneoxy group Chemical group 0.000 description 1
• 201000009961 allergic asthma Diseases 0.000 description 1
• 208000030961 allergic reaction Diseases 0.000 description 1
• 201000010105 allergic rhinitis Diseases 0.000 description 1
• 230000000735 allogeneic effect Effects 0.000 description 1
• 235000020224 almond Nutrition 0.000 description 1
• 231100000360 alopecia Toxicity 0.000 description 1
• HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
• 125000000266 alpha-aminoacyl group Chemical group 0.000 description 1
• 229910052782 aluminium Inorganic materials 0.000 description 1
• XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
• PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
• CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
• 229940063655 aluminum stearate Drugs 0.000 description 1
• 125000003368 amide group Chemical group 0.000 description 1
• KEFQYBOUFWLVHI-UHFFFAOYSA-N amino(cyclohexyl)carbamic acid Chemical compound OC(=O)N(N)C1CCCCC1 KEFQYBOUFWLVHI-UHFFFAOYSA-N 0.000 description 1
• 125000006598 aminocarbonylamino group Chemical group 0.000 description 1
• 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 1
• 125000004682 aminothiocarbonyl group Chemical group NC(=S)* 0.000 description 1
• 235000019257 ammonium acetate Nutrition 0.000 description 1
• 229940043376 ammonium acetate Drugs 0.000 description 1
• 235000019270 ammonium chloride Nutrition 0.000 description 1
• 150000003863 ammonium salts Chemical class 0.000 description 1
• 230000036783 anaphylactic response Effects 0.000 description 1
• 208000003455 anaphylaxis Diseases 0.000 description 1
• 206010002449 angioimmunoblastic T-cell lymphoma Diseases 0.000 description 1
• 150000001448 anilines Chemical class 0.000 description 1
• 210000004102 animal cell Anatomy 0.000 description 1
• 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
• 230000002429 anti-coagulating effect Effects 0.000 description 1
• 230000003302 anti-idiotype Effects 0.000 description 1
• 230000000781 anti-lymphocytic effect Effects 0.000 description 1
• 210000000612 antigen-presenting cell Anatomy 0.000 description 1
• 230000000890 antigenic effect Effects 0.000 description 1
• 229940125715 antihistaminic agent Drugs 0.000 description 1
• 239000000739 antihistaminic agent Substances 0.000 description 1
• 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 description 1
• 239000000074 antisense oligonucleotide Substances 0.000 description 1
• 238000012230 antisense oligonucleotides Methods 0.000 description 1
• 210000000436 anus Anatomy 0.000 description 1
• 210000000709 aorta Anatomy 0.000 description 1
• 238000013459 approach Methods 0.000 description 1
• 239000008346 aqueous phase Substances 0.000 description 1
• 239000007900 aqueous suspension Substances 0.000 description 1
• 229940114079 arachidonic acid Drugs 0.000 description 1
• 235000021342 arachidonic acid Nutrition 0.000 description 1
• 229960003121 arginine Drugs 0.000 description 1
• 150000004982 aromatic amines Chemical class 0.000 description 1
• 125000005100 aryl amino carbonyl group Chemical group 0.000 description 1
• 125000004658 aryl carbonyl amino group Chemical group 0.000 description 1
• 125000005129 aryl carbonyl group Chemical group 0.000 description 1
• 125000005199 aryl carbonyloxy group Chemical group 0.000 description 1
• 125000005162 aryl oxy carbonyl amino group Chemical group 0.000 description 1
• 125000005163 aryl sulfanyl group Chemical group 0.000 description 1
• 125000004657 aryl sulfonyl amino group Chemical group 0.000 description 1
• 125000004391 aryl sulfonyl group Chemical group 0.000 description 1
• 229940009098 aspartate Drugs 0.000 description 1
• 238000002820 assay format Methods 0.000 description 1
• 238000011914 asymmetric synthesis Methods 0.000 description 1
• 239000012298 atmosphere Substances 0.000 description 1
• 239000012752 auxiliary agent Substances 0.000 description 1
• 125000002393 azetidinyl group Chemical group 0.000 description 1
• 150000001540 azides Chemical class 0.000 description 1
• 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 1
• 229960004669 basiliximab Drugs 0.000 description 1
• 235000013871 bee wax Nutrition 0.000 description 1
• 239000012166 beeswax Substances 0.000 description 1
• 230000009286 beneficial effect Effects 0.000 description 1
• 229940077388 benzenesulfonate Drugs 0.000 description 1
• SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
• 125000003785 benzimidazolyl group Chemical class N1=C(NC2=C1C=CC=C2)* 0.000 description 1
• 229940050390 benzoate Drugs 0.000 description 1
• 235000019400 benzoyl peroxide Nutrition 0.000 description 1
• HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 1
• 125000000440 benzylamino group Chemical group [H]N(*)C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
• 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
• 230000005266 beta plus decay Effects 0.000 description 1
• MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
• 102000006635 beta-lactamase Human genes 0.000 description 1
• XMIIGOLPHOKFCH-UHFFFAOYSA-N beta-phenylpropanoic acid Natural products OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
• 229960003237 betaine Drugs 0.000 description 1
• 231100000693 bioaccumulation Toxicity 0.000 description 1
• 238000012742 biochemical analysis Methods 0.000 description 1
• 238000002306 biochemical method Methods 0.000 description 1
• 230000004071 biological effect Effects 0.000 description 1
• 230000031018 biological processes and functions Effects 0.000 description 1
• 230000033228 biological regulation Effects 0.000 description 1
• 230000008512 biological response Effects 0.000 description 1
• 230000005540 biological transmission Effects 0.000 description 1
• 239000004305 biphenyl Chemical group 0.000 description 1
• 235000010290 biphenyl Nutrition 0.000 description 1
• 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
• SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 1
• OGODKNYCTJYXFF-UHFFFAOYSA-N bis(4-methylbenzoyl) 2,3-dihydroxybutanedioate Chemical class C1=CC(C)=CC=C1C(=O)OC(=O)C(O)C(O)C(=O)OC(=O)C1=CC=C(C)C=C1 OGODKNYCTJYXFF-UHFFFAOYSA-N 0.000 description 1
• 210000003969 blast cell Anatomy 0.000 description 1
• 210000000601 blood cell Anatomy 0.000 description 1
• 230000037396 body weight Effects 0.000 description 1
• 210000002449 bone cell Anatomy 0.000 description 1
• 210000004556 brain Anatomy 0.000 description 1
• 208000000594 bullous pemphigoid Diseases 0.000 description 1
• HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 description 1
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
• 229910000024 caesium carbonate Inorganic materials 0.000 description 1
• 229960001948 caffeine Drugs 0.000 description 1
• VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
• 229940046731 calcineurin inhibitors Drugs 0.000 description 1
• 229910000389 calcium phosphate Inorganic materials 0.000 description 1
• 235000011010 calcium phosphates Nutrition 0.000 description 1
• 239000000378 calcium silicate Substances 0.000 description 1
• 229910052918 calcium silicate Inorganic materials 0.000 description 1
• 229960003340 calcium silicate Drugs 0.000 description 1
• 235000012241 calcium silicate Nutrition 0.000 description 1
• OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
• MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
• 208000035269 cancer or benign tumor Diseases 0.000 description 1
• 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
• 239000004202 carbamide Chemical class 0.000 description 1
• 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 1
• HJUGFYREWKUQJT-UHFFFAOYSA-N carbon tetrabromide Natural products BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 1
• JRZBPELLUMBLQU-UHFFFAOYSA-N carbonazidic acid Chemical compound OC(=O)N=[N+]=[N-] JRZBPELLUMBLQU-UHFFFAOYSA-N 0.000 description 1
• BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
• 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
• 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
• 150000007942 carboxylates Chemical class 0.000 description 1
• 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
• 230000000747 cardiac effect Effects 0.000 description 1
• 239000004359 castor oil Substances 0.000 description 1
• 235000019438 castor oil Nutrition 0.000 description 1
• 230000020411 cell activation Effects 0.000 description 1
• 238000004113 cell culture Methods 0.000 description 1
• 230000022131 cell cycle Effects 0.000 description 1
• 230000011712 cell development Effects 0.000 description 1
• 239000013592 cell lysate Substances 0.000 description 1
• 239000002771 cell marker Substances 0.000 description 1
• 210000000170 cell membrane Anatomy 0.000 description 1
• 230000006041 cell recruitment Effects 0.000 description 1
• 230000033077 cellular process Effects 0.000 description 1
• 229960000541 cetyl alcohol Drugs 0.000 description 1
• DGLFSNZWRYADFC-UHFFFAOYSA-N chembl2334586 Chemical compound C1CCC2=CN=C(N)N=C2C2=C1NC1=CC=C(C#CC(C)(O)C)C=C12 DGLFSNZWRYADFC-UHFFFAOYSA-N 0.000 description 1
• 238000005660 chlorination reaction Methods 0.000 description 1
• 125000001309 chloro group Chemical group Cl* 0.000 description 1
• OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
• 229960001231 choline Drugs 0.000 description 1
• 208000021668 chronic eosinophilic leukemia Diseases 0.000 description 1
• 201000010902 chronic myelomonocytic leukemia Diseases 0.000 description 1
• 201000010903 chronic neutrophilic leukemia Diseases 0.000 description 1
• 208000013056 classic Hodgkin lymphoma Diseases 0.000 description 1
• 230000015271 coagulation Effects 0.000 description 1
• 238000005345 coagulation Methods 0.000 description 1
• 239000011248 coating agent Substances 0.000 description 1
• 229940110456 cocoa butter Drugs 0.000 description 1
• 235000019868 cocoa butter Nutrition 0.000 description 1
• 239000008119 colloidal silica Substances 0.000 description 1
• 230000005757 colony formation Effects 0.000 description 1
• 239000003086 colorant Substances 0.000 description 1
• 238000005056 compaction Methods 0.000 description 1
• 230000000052 comparative effect Effects 0.000 description 1
• 230000000295 complement effect Effects 0.000 description 1
• 229940125877 compound 31 Drugs 0.000 description 1
• 229940125844 compound 46 Drugs 0.000 description 1
• 239000007891 compressed tablet Substances 0.000 description 1
• 238000007906 compression Methods 0.000 description 1
• 230000006835 compression Effects 0.000 description 1
• 239000000470 constituent Substances 0.000 description 1
• 208000010247 contact dermatitis Diseases 0.000 description 1
• 230000001276 controlling effect Effects 0.000 description 1
• 239000012059 conventional drug carrier Substances 0.000 description 1
• 229910052802 copper Inorganic materials 0.000 description 1
• 239000010949 copper Substances 0.000 description 1
• ORTQZVOHEJQUHG-UHFFFAOYSA-L copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 description 1
• GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 1
• 239000002285 corn oil Substances 0.000 description 1
• 235000005687 corn oil Nutrition 0.000 description 1
• 239000003246 corticosteroid Substances 0.000 description 1
• 229960001334 corticosteroids Drugs 0.000 description 1
• 239000002385 cottonseed oil Substances 0.000 description 1
• 235000012343 cottonseed oil Nutrition 0.000 description 1
• 238000002425 crystallisation Methods 0.000 description 1
• 230000008025 crystallization Effects 0.000 description 1
• 229960003280 cupric chloride Drugs 0.000 description 1
• 125000000000 cycloalkoxy group Chemical group 0.000 description 1
• 125000006254 cycloalkyl carbonyl group Chemical group 0.000 description 1
• 125000005169 cycloalkylcarbonylamino group Chemical group 0.000 description 1
• 125000005201 cycloalkylcarbonyloxy group Chemical group 0.000 description 1
• 125000005366 cycloalkylthio group Chemical group 0.000 description 1
• 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• UCZUCGRGTXIWLR-UHFFFAOYSA-N cyclohexyl hydrogen sulfate Chemical class OS(=O)(=O)OC1CCCCC1 UCZUCGRGTXIWLR-UHFFFAOYSA-N 0.000 description 1
• NISGSNTVMOOSJQ-UHFFFAOYSA-N cyclopentanamine Chemical compound NC1CCCC1 NISGSNTVMOOSJQ-UHFFFAOYSA-N 0.000 description 1
• BALGDZWGNCXXES-UHFFFAOYSA-N cyclopentane;propanoic acid Chemical compound CCC(O)=O.C1CCCC1 BALGDZWGNCXXES-UHFFFAOYSA-N 0.000 description 1
• 229960004397 cyclophosphamide Drugs 0.000 description 1
• ZOOSILUVXHVRJE-UHFFFAOYSA-N cyclopropanecarbonyl chloride Chemical compound ClC(=O)C1CC1 ZOOSILUVXHVRJE-UHFFFAOYSA-N 0.000 description 1
• 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
• 230000002559 cytogenic effect Effects 0.000 description 1
• 230000010250 cytokine signaling pathway Effects 0.000 description 1
• 230000001461 cytolytic effect Effects 0.000 description 1
• 208000024389 cytopenia Diseases 0.000 description 1
• 210000000805 cytoplasm Anatomy 0.000 description 1
• 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
• 229960002806 daclizumab Drugs 0.000 description 1
• 125000004856 decahydroquinolinyl group Chemical group N1(CCCC2CCCCC12)* 0.000 description 1
• 230000006735 deficit Effects 0.000 description 1
• 230000003412 degenerative effect Effects 0.000 description 1
• 230000001934 delay Effects 0.000 description 1
• 238000002716 delivery method Methods 0.000 description 1
• 210000004443 dendritic cell Anatomy 0.000 description 1
• 238000010511 deprotection reaction Methods 0.000 description 1
• 238000009795 derivation Methods 0.000 description 1
• 206010012601 diabetes mellitus Diseases 0.000 description 1
• 150000008050 dialkyl sulfates Chemical class 0.000 description 1
• 125000005265 dialkylamine group Chemical group 0.000 description 1
• 125000005266 diarylamine group Chemical group 0.000 description 1
• 125000004986 diarylamino group Chemical group 0.000 description 1
• NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
• 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
• 229940038472 dicalcium phosphate Drugs 0.000 description 1
• 235000005911 diet Nutrition 0.000 description 1
• 230000037213 diet Effects 0.000 description 1
• 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
• HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
• 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 description 1
• 230000004069 differentiation Effects 0.000 description 1
• 229940043279 diisopropylamine Drugs 0.000 description 1
• 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
• GAFRWLVTHPVQGK-UHFFFAOYSA-N dipentyl sulfate Chemical class CCCCCOS(=O)(=O)OCCCCC GAFRWLVTHPVQGK-UHFFFAOYSA-N 0.000 description 1
• MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 1
• 238000004821 distillation Methods 0.000 description 1
• MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
• 229940043264 dodecyl sulfate Drugs 0.000 description 1
• 230000003828 downregulation Effects 0.000 description 1
• 230000007783 downstream signaling Effects 0.000 description 1
• 230000002500 effect on skin Effects 0.000 description 1
• 239000012636 effector Substances 0.000 description 1
• 239000003792 electrolyte Substances 0.000 description 1
• 238000000921 elemental analysis Methods 0.000 description 1
• 230000008030 elimination Effects 0.000 description 1
• 238000003379 elimination reaction Methods 0.000 description 1
• 238000010828 elution Methods 0.000 description 1
• 238000004945 emulsification Methods 0.000 description 1
• 230000001804 emulsifying effect Effects 0.000 description 1
• 125000001240 enamine group Chemical group 0.000 description 1
• 210000003038 endothelium Anatomy 0.000 description 1
• 229940079360 enema for constipation Drugs 0.000 description 1
• 230000002708 enhancing effect Effects 0.000 description 1
• 230000007613 environmental effect Effects 0.000 description 1
• 230000002327 eosinophilic effect Effects 0.000 description 1
• 229960005139 epinephrine Drugs 0.000 description 1
• 230000000925 erythroid effect Effects 0.000 description 1
• 125000004185 ester group Chemical group 0.000 description 1
• CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
• CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical class CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
• BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
• 150000002170 ethers Chemical class 0.000 description 1
• RKXQOBNFWAVUQO-UHFFFAOYSA-N ethyl 2-chloro-4-[(1-methylindol-4-yl)amino]pyrimidine-5-carboxylate Chemical compound CCOC(=O)C1=CN=C(Cl)N=C1NC1=CC=CC2=C1C=CN2C RKXQOBNFWAVUQO-UHFFFAOYSA-N 0.000 description 1
• CAKXVDKUBNRHRY-UHFFFAOYSA-N ethyl 2-chloro-4-[(1-phenylmethoxycarbonylpiperidin-3-yl)methylamino]pyrimidine-5-carboxylate Chemical compound CCOC(=O)C1=CN=C(Cl)N=C1NCC1CN(C(=O)OCC=2C=CC=CC=2)CCC1 CAKXVDKUBNRHRY-UHFFFAOYSA-N 0.000 description 1
• 235000019325 ethyl cellulose Nutrition 0.000 description 1
• 229920001249 ethyl cellulose Polymers 0.000 description 1
• LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
• 229940093471 ethyl oleate Drugs 0.000 description 1
• 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
• 125000005290 ethynyloxy group Chemical group C(#C)O* 0.000 description 1
• ZXUMUPVQYAFTLF-UHFFFAOYSA-N etryptamine Chemical compound C1=CC=C2C(CC(N)CC)=CNC2=C1 ZXUMUPVQYAFTLF-UHFFFAOYSA-N 0.000 description 1
• 238000002474 experimental method Methods 0.000 description 1
• 210000002744 extracellular matrix Anatomy 0.000 description 1
• 208000019995 familial amyotrophic lateral sclerosis Diseases 0.000 description 1
• 230000002349 favourable effect Effects 0.000 description 1
• 229940012952 fibrinogen Drugs 0.000 description 1
• 238000011049 filling Methods 0.000 description 1
• 239000000796 flavoring agent Substances 0.000 description 1
• 239000012530 fluid Substances 0.000 description 1
• MDQRDWAGHRLBPA-UHFFFAOYSA-N fluoroamine Chemical group FN MDQRDWAGHRLBPA-UHFFFAOYSA-N 0.000 description 1
• 239000006260 foam Substances 0.000 description 1
• 235000003599 food sweetener Nutrition 0.000 description 1
• 235000019253 formic acid Nutrition 0.000 description 1
• 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
• 238000001640 fractional crystallisation Methods 0.000 description 1
• VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical compound [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
• 230000002538 fungal effect Effects 0.000 description 1
• 229940084434 fungoid Drugs 0.000 description 1
• 210000004475 gamma-delta t lymphocyte Anatomy 0.000 description 1
• 229940083124 ganglion-blocking antiadrenergic secondary and tertiary amines Drugs 0.000 description 1
• 230000002496 gastric effect Effects 0.000 description 1
• 238000007429 general method Methods 0.000 description 1
• 230000002068 genetic effect Effects 0.000 description 1
• 239000011521 glass Substances 0.000 description 1
• 229960002442 glucosamine Drugs 0.000 description 1
• 239000008103 glucose Substances 0.000 description 1
• 235000001727 glucose Nutrition 0.000 description 1
• ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
• 229960002449 glycine Drugs 0.000 description 1
• 208000024908 graft versus host disease Diseases 0.000 description 1
• 238000005469 granulation Methods 0.000 description 1
• 230000003179 granulation Effects 0.000 description 1
• 210000003714 granulocyte Anatomy 0.000 description 1
• 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 description 1
• 201000009277 hairy cell leukemia Diseases 0.000 description 1
• 150000004820 halides Chemical class 0.000 description 1
• 125000004438 haloalkoxy group Chemical group 0.000 description 1
• 125000001188 haloalkyl group Chemical group 0.000 description 1
• 230000036541 health Effects 0.000 description 1
• 238000010438 heat treatment Methods 0.000 description 1
• 210000002443 helper t lymphocyte Anatomy 0.000 description 1
• 230000002489 hematologic effect Effects 0.000 description 1
• 230000009033 hematopoietic malignancy Effects 0.000 description 1
• 210000000777 hematopoietic system Anatomy 0.000 description 1
• 208000034737 hemoglobinopathy Diseases 0.000 description 1
• 230000011132 hemopoiesis Effects 0.000 description 1
• 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 125000005223 heteroarylcarbonyl group Chemical group 0.000 description 1
• 125000005224 heteroarylcarbonylamino group Chemical group 0.000 description 1
• 125000005204 heteroarylcarbonyloxy group Chemical group 0.000 description 1
• 125000005553 heteroaryloxy group Chemical group 0.000 description 1
• 125000005226 heteroaryloxycarbonyl group Chemical group 0.000 description 1
• 125000005419 heteroarylsulfonylamino group Chemical group 0.000 description 1
• 125000005368 heteroarylthio group Chemical group 0.000 description 1
• 125000004415 heterocyclylalkyl group Chemical group 0.000 description 1
• 125000005844 heterocyclyloxy group Chemical group 0.000 description 1
• 125000004468 heterocyclylthio group Chemical group 0.000 description 1
• 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 238000013537 high throughput screening Methods 0.000 description 1
• 229960001340 histamine Drugs 0.000 description 1
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
• 230000003054 hormonal effect Effects 0.000 description 1
• 229940088597 hormone Drugs 0.000 description 1
• 239000005556 hormone Substances 0.000 description 1
• 238000009396 hybridization Methods 0.000 description 1
• XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
• 150000007857 hydrazones Chemical class 0.000 description 1
• BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical class [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
• 150000003840 hydrochlorides Chemical class 0.000 description 1
• XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
• 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
• 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
• 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
• 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
• UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
• 208000013403 hyperactivity Diseases 0.000 description 1
• 206010020718 hyperplasia Diseases 0.000 description 1
• AKQZEFRALAUBFS-UHFFFAOYSA-N ilamine Natural products COC(C)C(O)(C(=O)OCC1=CCN2CCCC12)C(C)(C)O AKQZEFRALAUBFS-UHFFFAOYSA-N 0.000 description 1
• 150000002460 imidazoles Chemical class 0.000 description 1
• MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
• 150000003949 imides Chemical class 0.000 description 1
• 229940072221 immunoglobulins Drugs 0.000 description 1
• 230000001506 immunosuppresive effect Effects 0.000 description 1
• 238000009169 immunotherapy Methods 0.000 description 1
• 238000002513 implantation Methods 0.000 description 1
• 230000002779 inactivation Effects 0.000 description 1
• 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
• 230000007574 infarction Effects 0.000 description 1
• 208000015181 infectious disease Diseases 0.000 description 1
• 230000008595 infiltration Effects 0.000 description 1
• 238000001764 infiltration Methods 0.000 description 1
• 230000028709 inflammatory response Effects 0.000 description 1
• 239000004615 ingredient Substances 0.000 description 1
• 229940102223 injectable solution Drugs 0.000 description 1
• 229940102213 injectable suspension Drugs 0.000 description 1
• 150000007529 inorganic bases Chemical class 0.000 description 1
• 150000002484 inorganic compounds Chemical class 0.000 description 1
• 229910010272 inorganic material Inorganic materials 0.000 description 1
• 235000013902 inosinic acid Nutrition 0.000 description 1
• 238000009434 installation Methods 0.000 description 1
• 238000007913 intrathecal administration Methods 0.000 description 1
• 229940125425 inverse agonist Drugs 0.000 description 1
• 239000011630 iodine Substances 0.000 description 1
• 229940044173 iodine-125 Drugs 0.000 description 1
• INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
• 239000003456 ion exchange resin Substances 0.000 description 1
• 229920003303 ion-exchange polymer Polymers 0.000 description 1
• 230000000302 ischemic effect Effects 0.000 description 1
• 210000004153 islets of langerhan Anatomy 0.000 description 1
• KDSNLYIMUZNERS-UHFFFAOYSA-N isobutyl amine Natural products CC(C)CN KDSNLYIMUZNERS-UHFFFAOYSA-N 0.000 description 1
• 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
• QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
• JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
• 230000000155 isotopic effect Effects 0.000 description 1
• 201000005992 juvenile myelomonocytic leukemia Diseases 0.000 description 1
• 210000001117 keloid Anatomy 0.000 description 1
• 238000000021 kinase assay Methods 0.000 description 1
• 238000011813 knockout mouse model Methods 0.000 description 1
• 201000003445 large cell neuroendocrine carcinoma Diseases 0.000 description 1
• 235000010445 lecithin Nutrition 0.000 description 1
• 239000000787 lecithin Substances 0.000 description 1
• 229940067606 lecithin Drugs 0.000 description 1
• 231100000518 lethal Toxicity 0.000 description 1
• 230000001665 lethal effect Effects 0.000 description 1
• 150000002617 leukotrienes Chemical class 0.000 description 1
• 150000002632 lipids Chemical class 0.000 description 1
• 239000002502 liposome Substances 0.000 description 1
• 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
• 239000008297 liquid dosage form Substances 0.000 description 1
• 239000006193 liquid solution Substances 0.000 description 1
• 239000006194 liquid suspension Substances 0.000 description 1
• 229910052744 lithium Inorganic materials 0.000 description 1
• 239000012280 lithium aluminium hydride Substances 0.000 description 1
• 230000007774 longterm Effects 0.000 description 1
• 239000007937 lozenge Substances 0.000 description 1
• 201000005249 lung adenocarcinoma Diseases 0.000 description 1
• 201000005296 lung carcinoma Diseases 0.000 description 1
• 210000004324 lymphatic system Anatomy 0.000 description 1
• 231100001023 lymphopenia Toxicity 0.000 description 1
• 201000007919 lymphoplasmacytic lymphoma Diseases 0.000 description 1
• 239000008176 lyophilized powder Substances 0.000 description 1
• ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
• 239000001095 magnesium carbonate Substances 0.000 description 1
• 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
• 159000000003 magnesium salts Chemical class 0.000 description 1
• 230000014759 maintenance of location Effects 0.000 description 1
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
• 150000002690 malonic acid derivatives Chemical class 0.000 description 1
• MMIPFLVOWGHZQD-UHFFFAOYSA-N manganese(3+) Chemical compound [Mn+3] MMIPFLVOWGHZQD-UHFFFAOYSA-N 0.000 description 1
• 239000003550 marker Substances 0.000 description 1
• 238000004949 mass spectrometry Methods 0.000 description 1
• 238000001819 mass spectrum Methods 0.000 description 1
• 208000020968 mature T-cell and NK-cell non-Hodgkin lymphoma Diseases 0.000 description 1
• 230000010534 mechanism of action Effects 0.000 description 1
• 238000002483 medication Methods 0.000 description 1
• 239000002609 medium Substances 0.000 description 1
• 238000002844 melting Methods 0.000 description 1
• 230000008018 melting Effects 0.000 description 1
• 201000008350 membranous glomerulonephritis Diseases 0.000 description 1
• 208000030159 metabolic disease Diseases 0.000 description 1
• 230000002503 metabolic effect Effects 0.000 description 1
• 239000002207 metabolite Substances 0.000 description 1
• 230000009401 metastasis Effects 0.000 description 1
• 230000001394 metastastic effect Effects 0.000 description 1
• 206010061289 metastatic neoplasm Diseases 0.000 description 1
• 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
• 229920000609 methyl cellulose Polymers 0.000 description 1
• 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
• 230000011987 methylation Effects 0.000 description 1
• 238000007069 methylation reaction Methods 0.000 description 1
• 235000010981 methylcellulose Nutrition 0.000 description 1
• 239000001923 methylcellulose Substances 0.000 description 1
• 125000004092 methylthiomethyl group Chemical group [H]C([H])([H])SC([H])([H])* 0.000 description 1
• 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
• 239000008108 microcrystalline cellulose Substances 0.000 description 1
• 229940016286 microcrystalline cellulose Drugs 0.000 description 1
• 206010027599 migraine Diseases 0.000 description 1
• 230000005012 migration Effects 0.000 description 1
• 238000013508 migration Methods 0.000 description 1
• 239000007932 molded tablet Substances 0.000 description 1
• 125000002950 monocyclic group Chemical group 0.000 description 1
• VSEAAEQOQBMPQF-UHFFFAOYSA-N morpholin-3-one Chemical group O=C1COCCN1 VSEAAEQOQBMPQF-UHFFFAOYSA-N 0.000 description 1
• 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
• 229940113083 morpholine Drugs 0.000 description 1
• 125000002757 morpholinyl group Chemical group 0.000 description 1
• 229940124303 multikinase inhibitor Drugs 0.000 description 1
• 230000035772 mutation Effects 0.000 description 1
• 229960000951 mycophenolic acid Drugs 0.000 description 1
• 206010028537 myelofibrosis Diseases 0.000 description 1
• 210000003643 myeloid progenitor cell Anatomy 0.000 description 1
• 230000002107 myocardial effect Effects 0.000 description 1
• 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• KVKFRMCSXWQSNT-UHFFFAOYSA-N n,n'-dimethylethane-1,2-diamine Chemical compound CNCCNC KVKFRMCSXWQSNT-UHFFFAOYSA-N 0.000 description 1
• FMASTMURQSHELY-UHFFFAOYSA-N n-(4-fluoro-2-methylphenyl)-3-methyl-n-[(2-methyl-1h-indol-4-yl)methyl]pyridine-4-carboxamide Chemical compound C1=CC=C2NC(C)=CC2=C1CN(C=1C(=CC(F)=CC=1)C)C(=O)C1=CC=NC=C1C FMASTMURQSHELY-UHFFFAOYSA-N 0.000 description 1
• UTIYIQPKIWWWCY-UHFFFAOYSA-N n-chloro-n-phenylpiperazin-1-amine Chemical compound C=1C=CC=CC=1N(Cl)N1CCNCC1 UTIYIQPKIWWWCY-UHFFFAOYSA-N 0.000 description 1
• NNKPHNTWNILINE-UHFFFAOYSA-N n-cyclopropyl-3-fluoro-4-methyl-5-[3-[[1-[2-[2-(methylamino)ethoxy]phenyl]cyclopropyl]amino]-2-oxopyrazin-1-yl]benzamide Chemical compound CNCCOC1=CC=CC=C1C1(NC=2C(N(C=3C(=C(F)C=C(C=3)C(=O)NC3CC3)C)C=CN=2)=O)CC1 NNKPHNTWNILINE-UHFFFAOYSA-N 0.000 description 1
• VDKZSHONJYADKP-UHFFFAOYSA-N n-phenylpiperazin-1-amine Chemical compound C1CNCCN1NC1=CC=CC=C1 VDKZSHONJYADKP-UHFFFAOYSA-N 0.000 description 1
• KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
• 125000001624 naphthyl group Chemical group 0.000 description 1
• 239000007922 nasal spray Substances 0.000 description 1
• 239000006199 nebulizer Substances 0.000 description 1
• 230000017074 necrotic cell death Effects 0.000 description 1
• 230000004770 neurodegeneration Effects 0.000 description 1
• 208000015122 neurodegenerative disease Diseases 0.000 description 1
• 230000000626 neurodegenerative effect Effects 0.000 description 1
• 239000002858 neurotransmitter agent Substances 0.000 description 1
• 235000001968 nicotinic acid Nutrition 0.000 description 1
• 239000011664 nicotinic acid Substances 0.000 description 1
• 150000002823 nitrates Chemical class 0.000 description 1
• 125000002560 nitrile group Chemical group 0.000 description 1
• 125000000018 nitroso group Chemical group N(=O)* 0.000 description 1
• 208000025275 nodular sclerosis classical Hodgkin lymphoma Diseases 0.000 description 1
• 231100000344 non-irritating Toxicity 0.000 description 1
• 102000037979 non-receptor tyrosine kinases Human genes 0.000 description 1
• 108091008046 non-receptor tyrosine kinases Proteins 0.000 description 1
• 230000000683 nonmetastatic effect Effects 0.000 description 1
• 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 210000004940 nucleus Anatomy 0.000 description 1
• 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
• 230000000771 oncological effect Effects 0.000 description 1
• 238000010915 one-step procedure Methods 0.000 description 1
• 230000003287 optical effect Effects 0.000 description 1
• 150000002894 organic compounds Chemical class 0.000 description 1
• KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 1
• 230000003647 oxidation Effects 0.000 description 1
• 238000007254 oxidation reaction Methods 0.000 description 1
• 150000002923 oximes Chemical class 0.000 description 1
• RZXMPPFPUUCRFN-UHFFFAOYSA-N p-toluidine Chemical compound CC1=CC=C(N)C=C1 RZXMPPFPUUCRFN-UHFFFAOYSA-N 0.000 description 1
• 239000003002 pH adjusting agent Substances 0.000 description 1
• 238000012856 packing Methods 0.000 description 1
• 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 201000002528 pancreatic cancer Diseases 0.000 description 1
• 208000008443 pancreatic carcinoma Diseases 0.000 description 1
• 239000002245 particle Substances 0.000 description 1
• 230000008506 pathogenesis Effects 0.000 description 1
• 230000001717 pathogenic effect Effects 0.000 description 1
• 230000001575 pathological effect Effects 0.000 description 1
• 230000009054 pathological process Effects 0.000 description 1
• 239000000312 peanut oil Substances 0.000 description 1
• 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
• 230000035699 permeability Effects 0.000 description 1
• JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
• 230000002085 persistent effect Effects 0.000 description 1
• 239000003208 petroleum Substances 0.000 description 1
• 125000003395 phenylethylamino group Chemical group [H]N(*)C([H])([H])C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
• UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Chemical group O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
• 210000004214 philadelphia chromosome Anatomy 0.000 description 1
• 150000003905 phosphatidylinositols Chemical class 0.000 description 1
• 150000003016 phosphoric acids Chemical class 0.000 description 1
• LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical class [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 description 1
• 230000000704 physical effect Effects 0.000 description 1
• 230000004962 physiological condition Effects 0.000 description 1
• 229940075930 picrate Drugs 0.000 description 1
• OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
• IWELDVXSEVIIGI-UHFFFAOYSA-N piperazin-2-one Chemical compound O=C1CNCCN1 IWELDVXSEVIIGI-UHFFFAOYSA-N 0.000 description 1
• 150000003053 piperidines Chemical class 0.000 description 1
• 125000003386 piperidinyl group Chemical group 0.000 description 1
• IUGYQRQAERSCNH-UHFFFAOYSA-M pivalate Chemical compound CC(C)(C)C([O-])=O IUGYQRQAERSCNH-UHFFFAOYSA-M 0.000 description 1
• 229950010765 pivalate Drugs 0.000 description 1
• 210000002381 plasma Anatomy 0.000 description 1
• BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
• 150000003057 platinum Chemical class 0.000 description 1
• 239000002798 polar solvent Substances 0.000 description 1
• 229920000058 polyacrylate Polymers 0.000 description 1
• 229920000573 polyethylene Polymers 0.000 description 1
• 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
• 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
• 229940113124 polysorbate 60 Drugs 0.000 description 1
• LZMJNVRJMFMYQS-UHFFFAOYSA-N poseltinib Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC1=NC(OC=2C=C(NC(=O)C=C)C=CC=2)=C(OC=C2)C2=N1 LZMJNVRJMFMYQS-UHFFFAOYSA-N 0.000 description 1
• 230000002980 postoperative effect Effects 0.000 description 1
• 239000011591 potassium Substances 0.000 description 1
• NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 1
• 229910000160 potassium phosphate Inorganic materials 0.000 description 1
• 235000011009 potassium phosphates Nutrition 0.000 description 1
• 159000000001 potassium salts Chemical class 0.000 description 1
• 239000004302 potassium sorbate Substances 0.000 description 1
• 235000010241 potassium sorbate Nutrition 0.000 description 1
• 229940069338 potassium sorbate Drugs 0.000 description 1
• WVULZDFWPQCPPJ-UHFFFAOYSA-N potassium;hydrochloride Chemical compound Cl.[K] WVULZDFWPQCPPJ-UHFFFAOYSA-N 0.000 description 1
• 238000001556 precipitation Methods 0.000 description 1
• 238000004321 preservation Methods 0.000 description 1
• 230000002335 preservative effect Effects 0.000 description 1
• 150000003141 primary amines Chemical class 0.000 description 1
• 238000012545 processing Methods 0.000 description 1
• 238000004393 prognosis Methods 0.000 description 1
• 230000000750 progressive effect Effects 0.000 description 1
• TURAMGVWNUTQKH-UHFFFAOYSA-N propa-1,2-dien-1-one Chemical group C=C=C=O TURAMGVWNUTQKH-UHFFFAOYSA-N 0.000 description 1
• 230000000069 prophylactic effect Effects 0.000 description 1
• 238000011321 prophylaxis Methods 0.000 description 1
• LZFIOSVZIQOVFW-UHFFFAOYSA-N propyl 2-hydroxybenzoate Chemical class CCCOC(=O)C1=CC=CC=C1O LZFIOSVZIQOVFW-UHFFFAOYSA-N 0.000 description 1
• 235000013772 propylene glycol Nutrition 0.000 description 1
• 229950008679 protamine sulfate Drugs 0.000 description 1
• 239000003909 protein kinase inhibitor Substances 0.000 description 1
• 108020000494 protein-tyrosine phosphatase Proteins 0.000 description 1
• 208000005069 pulmonary fibrosis Diseases 0.000 description 1
• 238000000746 purification Methods 0.000 description 1
• 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
• 125000003373 pyrazinyl group Chemical group 0.000 description 1
• JEXVQSWXXUJEMA-UHFFFAOYSA-N pyrazol-3-one Chemical compound O=C1C=CN=N1 JEXVQSWXXUJEMA-UHFFFAOYSA-N 0.000 description 1
• 150000003217 pyrazoles Chemical class 0.000 description 1
• DNXIASIHZYFFRO-UHFFFAOYSA-N pyrazoline Chemical compound C1CN=NC1 DNXIASIHZYFFRO-UHFFFAOYSA-N 0.000 description 1
• 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
• 230000009257 reactivity Effects 0.000 description 1
• 108091006082 receptor inhibitors Proteins 0.000 description 1
• 229940100618 rectal suppository Drugs 0.000 description 1
• 239000006215 rectal suppository Substances 0.000 description 1
• 210000000664 rectum Anatomy 0.000 description 1
• 238000010992 reflux Methods 0.000 description 1
• 238000011160 research Methods 0.000 description 1
• 201000006845 reticulosarcoma Diseases 0.000 description 1
• 208000029922 reticulum cell sarcoma Diseases 0.000 description 1
• 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
• 238000012552 review Methods 0.000 description 1
• 150000003902 salicylic acid esters Chemical class 0.000 description 1
• 230000037390 scarring Effects 0.000 description 1
• 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
• XIIOFHFUYBLOLW-UHFFFAOYSA-N selpercatinib Chemical compound OC(COC=1C=C(C=2N(C=1)N=CC=2C#N)C=1C=NC(=CC=1)N1CC2N(C(C1)C2)CC=1C=NC(=CC=1)OC)(C)C XIIOFHFUYBLOLW-UHFFFAOYSA-N 0.000 description 1
• 230000035945 sensitivity Effects 0.000 description 1
• 229940076279 serotonin Drugs 0.000 description 1
• 206010040400 serum sickness Diseases 0.000 description 1
• 239000008159 sesame oil Substances 0.000 description 1
• 235000011803 sesame oil Nutrition 0.000 description 1
• 230000009476 short term action Effects 0.000 description 1
• 102000035025 signaling receptors Human genes 0.000 description 1
• 108091005475 signaling receptors Proteins 0.000 description 1
• 229910052710 silicon Inorganic materials 0.000 description 1
• 239000010703 silicon Substances 0.000 description 1
• XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 1
• 238000009097 single-agent therapy Methods 0.000 description 1
• 238000004513 sizing Methods 0.000 description 1
• 210000000813 small intestine Anatomy 0.000 description 1
• 210000002460 smooth muscle Anatomy 0.000 description 1
• 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
• 235000017557 sodium bicarbonate Nutrition 0.000 description 1
• 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
• WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
• 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
• 229910000029 sodium carbonate Inorganic materials 0.000 description 1
• 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
• 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
• 239000011780 sodium chloride Substances 0.000 description 1
• 239000001509 sodium citrate Substances 0.000 description 1
• 239000012312 sodium hydride Substances 0.000 description 1
• 229910000104 sodium hydride Inorganic materials 0.000 description 1
• 235000010288 sodium nitrite Nutrition 0.000 description 1
• 229910052938 sodium sulfate Inorganic materials 0.000 description 1
• 235000011152 sodium sulphate Nutrition 0.000 description 1
• ILJOYZVVZZFIKA-UHFFFAOYSA-M sodium;1,1-dioxo-1,2-benzothiazol-3-olate;hydrate Chemical compound O.[Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 ILJOYZVVZZFIKA-UHFFFAOYSA-M 0.000 description 1
• 230000003381 solubilizing effect Effects 0.000 description 1
• 239000012453 solvate Substances 0.000 description 1
• 239000004334 sorbic acid Substances 0.000 description 1
• 235000010199 sorbic acid Nutrition 0.000 description 1
• 229940075582 sorbic acid Drugs 0.000 description 1
• 230000001148 spastic effect Effects 0.000 description 1
• 230000009870 specific binding Effects 0.000 description 1
• 230000003595 spectral effect Effects 0.000 description 1
• 125000003003 spiro group Chemical group 0.000 description 1
• 210000000952 spleen Anatomy 0.000 description 1
• 238000010186 staining Methods 0.000 description 1
• 238000010561 standard procedure Methods 0.000 description 1
• 239000012058 sterile packaged powder Substances 0.000 description 1
• 150000003431 steroids Chemical class 0.000 description 1
• 210000002784 stomach Anatomy 0.000 description 1
• KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
• KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 1
• IIACRCGMVDHOTQ-UHFFFAOYSA-N sulfamic acid Chemical class NS(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 description 1
• 125000004646 sulfenyl group Chemical class S(*)* 0.000 description 1
• BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
• 125000003375 sulfoxide group Chemical group 0.000 description 1
• 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
• 239000013589 supplement Substances 0.000 description 1
• 230000001502 supplementing effect Effects 0.000 description 1
• 238000001356 surgical procedure Methods 0.000 description 1
• 230000002889 sympathetic effect Effects 0.000 description 1
• 238000001308 synthesis method Methods 0.000 description 1
• RZDKHKXBRIBDIN-UHFFFAOYSA-N tert-butyl 2-oxopiperidine-4-carboxylate Chemical compound CC(C)(C)OC(=O)C1CCNC(=O)C1 RZDKHKXBRIBDIN-UHFFFAOYSA-N 0.000 description 1
• DSXFEYYTYBXYMB-UHFFFAOYSA-N tert-butyl 4-(aminomethyl)piperidine-1-carboxylate;hydrochloride Chemical compound Cl.CC(C)(C)OC(=O)N1CCC(CN)CC1 DSXFEYYTYBXYMB-UHFFFAOYSA-N 0.000 description 1
• 125000006318 tert-butyl amino group Chemical group [H]N(*)C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 1
• YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 1
• 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• HJUGFYREWKUQJT-OUBTZVSYSA-N tetrabromomethane Chemical compound Br[13C](Br)(Br)Br HJUGFYREWKUQJT-OUBTZVSYSA-N 0.000 description 1
• 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
• 150000003536 tetrazoles Chemical class 0.000 description 1
• 230000008719 thickening Effects 0.000 description 1
• 150000007970 thio esters Chemical class 0.000 description 1
• 125000003441 thioacyl group Chemical group 0.000 description 1
• 125000005296 thioaryloxy group Chemical group 0.000 description 1
• 125000000101 thioether group Chemical group 0.000 description 1
• 150000003573 thiols Chemical class 0.000 description 1
• 206010043778 thyroiditis Diseases 0.000 description 1
• 230000000451 tissue damage Effects 0.000 description 1
• 231100000827 tissue damage Toxicity 0.000 description 1
• 230000008467 tissue growth Effects 0.000 description 1
• YXFVVABEGXRONW-UHFFFAOYSA-N toluene Substances CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 1
• 239000012049 topical pharmaceutical composition Substances 0.000 description 1
• 235000010487 tragacanth Nutrition 0.000 description 1
• 239000000196 tragacanth Substances 0.000 description 1
• 229940116362 tragacanth Drugs 0.000 description 1
• 230000002103 transcriptional effect Effects 0.000 description 1
• 238000012546 transfer Methods 0.000 description 1
• 230000009261 transgenic effect Effects 0.000 description 1
• 230000001052 transient effect Effects 0.000 description 1
• 238000003146 transient transfection Methods 0.000 description 1
• 238000011269 treatment regimen Methods 0.000 description 1
• 150000003852 triazoles Chemical class 0.000 description 1
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
• 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
• 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
• 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 description 1
• YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
• HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
• 229940038773 trisodium citrate Drugs 0.000 description 1
• 229910052722 tritium Inorganic materials 0.000 description 1
• 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
• 229960000281 trometamol Drugs 0.000 description 1
• 239000002750 tryptase inhibitor Substances 0.000 description 1
• 208000025883 type III hypersensitivity disease Diseases 0.000 description 1
• ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
• 125000002948 undecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 201000005112 urinary bladder cancer Diseases 0.000 description 1
• 239000004474 valine Substances 0.000 description 1
• 230000003156 vasculitic effect Effects 0.000 description 1
• 239000005526 vasoconstrictor agent Substances 0.000 description 1
• 235000013311 vegetables Nutrition 0.000 description 1
• 210000003462 vein Anatomy 0.000 description 1
• 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
• 229920002554 vinyl polymer Polymers 0.000 description 1
• 108010047303 von Willebrand Factor Proteins 0.000 description 1
• 102100036537 von Willebrand factor Human genes 0.000 description 1
• 229960001134 von willebrand factor Drugs 0.000 description 1
• 238000001262 western blot Methods 0.000 description 1
• 235000021119 whey protein Nutrition 0.000 description 1
• 210000002268 wool Anatomy 0.000 description 1
• 150000003751 zinc Chemical class 0.000 description 1
• 229910052725 zinc Inorganic materials 0.000 description 1
• 239000011701 zinc Substances 0.000 description 1